Solvatochromic Fluorescent 2-Substituted 3-Ethynyl Quinoxalines: Four-Component Synthesis, Photophysical Properties, and Electronic Structure

Charlotte F. Gers,[†] Jan Nordmann,[†] Ceyda Kumru,[†] Walter Frank,[‡] and Thomas J. J. Müller^{*,†}

[†]Institut für Organische Chemie und Makromolekulare Chemie and [‡]Institut für Anorganische Chemie und Strukturchemie, Heinrich-Heine Universität Düsseldorf, Universitätstrasse 1, D-40225 Düsseldorf, Germany

Supporting Information

ABSTRACT: 2-Substituted 3-ethynylquinoxalines can be rapidly synthesized in generally excellent yields by a consecutive four-component synthesis starting from electronrich π -nucleophiles, oxalyl chloride, terminal alkynes, and 1,2-diaminoarenes. The title compounds are highly fluorescent with a pronounced emission solvatochromism. The photophysical properties and electronic structure were additionally corroborated by computations on the DFT level of theory.



■ INTRODUCTION

Over the past two decades, organic electronics have grown to an important field of interest in academia as well as in industry, providing crucial advantages over silicon-based electronics, such as low cost, flexibility, and functionality.¹ Due to the constant demand for novel tailor-made functional π -systems, new and reliable accesses toward such compounds have to be established. Diversity-oriented syntheses (DOS) are highly advantageous for synthetically exploring structural and functional characteristics because variation of the individual components leads to a heterogenic product library.² Among DOS, multicomponent reactions (MCRs)³ and one-pot strategies are economically and ecologically favorable, since higher resource efficiency is combined with lower waste production in comparison to traditional multistep synthesis.⁴ The concatenation of transitionmetal-catalyzed reactions in one-pot processes as the liaison of their unique reactivity patterns with fundamental organic reactivity allows for convenient accesses to reactive intermediates and their in situ conversion.⁵ While MCR approaches have regularly been employed in syntheses of natural products, pharmaceutically interesting compounds,⁶ and in combination with high-throughput screening in medicinal chemistry, their full potential in the field of functional π -systems just has begun to be exploited.^{2a,b} Most rewardingly, MCRs are ideally suited for rationally designing compound libraries for studying structure-property relationships.

Among myriad nitrogen-containing heterocycles that are ubiquitous in natural products and biological active compounds⁷ as well as structural units in functional π -systems,⁸ quinoxalines are particularly interesting. Many derivatives possess antitubercular,⁹ antibiotic,¹⁰ and anticancer activity,¹¹ and more-over, they are constantly studied due to their photophysical

properties.¹² For instance, Kudo et al. reported the synthesis of a quinoxaline-based push—pull system, which was found to quantitatively screen protein binding-site polarity of bovine serum albumine as a consequence of its pronounced emission solvatochromism.¹³ Lin et al. synthesized a set of chromophores based upon 2,3,5-trisubstituted quinoxaline cores, which display two-photon absorption properties.¹⁴ Faust et al. synthesized related 2,3-bisethynylquinoxalines through the condensation of dialkynyl-1,2-diones and 1,2-diaminoarenes.¹⁵ Their acetylenic quinoxalinoporphyrazine derivatives are potential candidates as photosensitizers in photodynamic therapy.¹⁶

We have recently reported a straightforward and modular one-pot approach to the densely functionalized but yet scarcely explored class of ynediones, starting from electron-rich π -nucleophiles, oxalyl chloride, and terminal alkynes (Scheme 1, path 1).¹⁷ The sequence starts with a Lewis acid free Friedel-Crafts acylation of the π -nucleophile with oxalyl chloride. The generated glyoxyl chloride is directly converted into the ynedione by applying a Cu(I)-catalyzed Stephens-Castro alkynylation. The employment of CuI as the single catalyst is crucial for the success of the ynedione formation as the Pd/Cu-catalyzed Sonogashira protocol¹⁸ leads to decarbonylation and eventually to the formation of ynones.¹⁹ Furthermore, the Cu(I)-catalyzed variant²⁰ does not require complex ligands. An alternative route to ynediones starts from glyoxylic acids and oxalyl chloride and the subsequent transformation of the glyoxyl chloride with alkynes (Scheme 1, path 2).²¹ Both methodologies allow for the introduction of a wide range of substituents to the ynedione core.

Received: November 22, 2013



Ynediones are highly valuable intermediates for the synthesis of various heterocyclic systems,²² and we have illustrated that both the Michael system or the dione motif can be addressed in the final step of a consecutive one-pot sequence.¹⁷ For instance, phenylamidine selectively reacts with the Michael acceptor furnishing a 4-acylpyrimidine, whereas 1,2-diaminobenzene exclusively addresses the dione motif to form a 2-substituted 3-ethynylquinoxaline (Scheme 2).

Scheme 2. Retrosynthetic Convergence of 4-Acylpyrimidines and 2-Substituted 3-Ethynylquinoxalines to Ynediones



Surprisingly, ethynylquinoxalines have only been scarcely studied. Ames et al. reported a Sonogashira-type reaction of 2-chloroquinoxaline with terminal alkynes to give 2-ethynylquinoxalines as precursors for the synthesis of pyrido[l,2-*a*]-quinoxalin-4-ones.²³ To our knowledge, only one ring-forming synthesis of 2-(hetero)aryl-substituted 3-ethynylquinoxalines has been reported so far,²⁴ where 1,2-diaminobenzene is reacted with two molecules of a terminal alkyne under Cu(I)-catalysis. However, this methodology can only generate 2-substituted 3-ethynylquinoxalines, which have identical substituents for R¹ and R².

Furthermore, we discovered via the naked eye that the 2-substituted 3-ethynylquinoxalines are highly fluorescent both in solution and in the solid state. In addition, test tube experiments indicated a pronounced emission solvatochromism.²⁵ The solvent-polarity sensitivity of solvatochromic fluorophores has found wide application in studies on protein biochemistry.²⁶

Since our multicomponent entry toward 2-(hetero)aryl-substituted 3-ethynylquinoxalines allows for a high degree of structural and functional variation due to its toolbox conception, we became intrigued to further explore this potential to luminescent derivatives. Here, we report the improved three-component synthesis of fluorescent 3-ethynylquinoxalines through a glyoxylation— Stephens—Castro coupling, as well as a study of the photophysical properties and electronic structure of this substance class.

RESULTS AND DISCUSSION

Synthesis. First optimization studies of the threecomponent ynedione synthesis with respect to substrate concentration, temperature, solvent, and reaction times were carried out on our previously used model system¹⁷ consisting of *N*-methylindole (1a) and phenylacetylene (2a) furnishing the ynedione 3a (Table 1).

The original conditions for the steps of the glyoxylation– alkynylation sequence¹⁷ at room temperature required 4 and 24 h, respectively (Table 1, entry 1). By raising the temperature

Table 1. Optimization Study for the Synthesis of Ynedione 3a



entry ^a	c ₀ (1a) (M)	solvent	Т (°С)	$\begin{pmatrix} t_1 \\ (h) \end{pmatrix}$	c ₀ (2a) (M)	$\begin{pmatrix} t_2 \\ (h) \end{pmatrix}$	ynedione 3a ^b (%)
1	0.2	THF	rt	4	0.2	24	64
2	0.2	THF	50	1	0.2	6	63
3	0.4	THF	50	1	0.4	6	69
4	0.4	THF	50	1	0.4	4	61
5	0.4	1,4-dioxane	rt	1	0.4	6	67
6	0.4	CH_2Cl_2	rt	1	0.4	6	38
7	0.4	1,2- dichloroethane	rt	1	0.4	6	56

"All reactions were performed on a 2.00 mmol scale. ^bYields after chromatography on silica gel.

for the glyoxylation step to 50 °C (Table 1, entry 2) and simultaneously increasing the concentration of **1a** and **2a** the reaction times of both steps were reduced to 1 and 6 h, respectively, while the yield slightly improved (Table 1, entry 3). However, further shortening of the reaction time resulted in a decreased yield (Table 1, entry 4). In addition, we found that 1,4-dioxane can be equally well used as solvent (Table 1, entry 5), whereas dichloromethane and 1,2-dichloroethane give lower yields (Table 1, entries 6 and 7).

With these optimized conditions (Table 1, entry 3) for the ynedione formation in hand and the time for the terminal cyclocondensation reduced from 3 h¹⁷ to 1 h, the consecutive four-component synthesis of 3-ethynylquinoxaline **5a** was performed in a total reaction time of 8 h (cf. 31 h)¹⁷ and with slightly improved yields from 72%¹⁷ to now 80% (Scheme 3).

Scheme 3. Optimized Conditions for the Four-Component Synthesis of 3-Ethynylquinoxaline 5a



The optimized conditions were applied in the four-component synthesis of various 3-ethynylquinoxalines **5** with different substitution patterns (Scheme 4, Table 2). Much to our delight, the sequence represents a modular approach to a substance library

Scheme 4. Consecutive Four-Component Synthesis of 3-Ethynylquinoxalines 5 with Glyoxylation–Alkynylation– Cyclocondensation Sequence



in moderate to excellent yields. The components π -nucleophile 1, alkyne 2, and 1,2-diaminoarene 4 can be varied within a wide range, and it is noteworthy to mention that all four components are applied in strictly equimolar ratios.

Aryl- (5a, 5d-i) as well as silvl-substituted alkynes (5b,c) can be successfully employed in the synthesis, whereas aliphatic alkynes only sluggishly undergo the Stephens-Castro coupling step. The π -nucleophile can vary from 1-methylindole (5a), differently N-substituted pyrroles (5j-o), and 2-methoxythiophene (5p-r) to azulene (5s). Expectedly, the initial glyoxylation, i.e., an electrophilic substitution reaction, regioselectively occurs for indoles at the 3-position for pyrroles at the 2-position with the exception of N-TIPS-pyrrole (50) for steric reasons. Although the nucleophilicity of the substrates slightly differs according to Mayr's scale,²⁷ all glyoxylations reach full conversion at 50 °C. It is noteworthy to mention that a further increase of the reaction temperature does not improve the yields. In the final cyclocondensation step, the employed 1,2-diaminoarenes 4 react equally well for the 4,5-dichloro (5t) and 4-nitro derivative (5u) as well as 2,3-diaminopyridine (5v) giving good yields. However, 1,2-diamino-4-nitrobenzene (4c) and 2,3-diaminopyridine (4d) give mixtures of regioisomers due to the different nucleophilicities of the amino nitrogen atoms. Based upon electronic effects of the substituents on both the dione and the diamine motif the major isomer presumably arises from the attack of the more nucleophilic amino group at the alkynyl conjugated carbonyl group. Additionally, 2,3-diaminonaphthalene (4e) furnishes benzo[g]quinoxalines (5w,x) with lower yields, which can be rationalized by the poor solubility of the products, which effects a complicated work up procedure.

While the glyoxylation approach is limited to electron-rich heterocycles at the 2-position of the quinoxalines due to the initial electrophilic glyoxylation, we expanded the scope of the substitution pattern by initiating the ynedione formation through activation—Stephens—Castro coupling (see Scheme 1, path 2). This approach also enables the introduction of electroneutral substituents at position 2 of the 3-ethynylquinoxalines 7 starting from glyoxylic acids **6** in the sense of a three-component activation—Stephens—Castro coupling—cyclocondensation sequence in moderate to good yields (Scheme 5, Table 3).

The molecular structures of the 3-ethynylquinoxalines **5** and 7 were unambiguously supported by ¹H and ¹³C NMR spectroscopy, mass spectrometry, and combustion analysis. Later, the structures were additionally corroborated by X-ray diffraction analysis of compounds **5d**, **5n**, **5q**, and **5x**.²⁸ Expectedly, in the solid state the quinoxaline core and the arylethynyl substituent are coplanarily alligned in all cases. However, the torsion angle between the 2-substituent and the quinoxaline core varies with the steric bulk of this substituent. For the 2-methoxythienyl derivative **5q** both moieties are almost coplanarily alligned, while for the 1-methylindole derivatives **5d** and **5x** this substituent is slightly twisted out of coplanarity by 13.2 and 16.2°, respectively. For the 1-phenylpyrrole substituent in compound **5q**, this torsion increases to 44.6° as a consequence of its bulky nature.

A closer analysis of the crystallographic data revealed the strong tendency of the molecules to build up pairs in the solid state, which are mostly caused by $\pi-\pi$ -interactions (Figure 1, left). These pairs are arranged in columns, which resemble a herringbone pattern (Figure 1, right).

Within the pairs, the angle between the best planes of the π systems in close contact, namely the six-membered ring of the anisole fragment and the neighboring quinoxaline fragment, is 7.4°. The distances between the atoms of the six-membered ring of the anisole fragment to the best plane of the quinoxaline fragment range from 329.3(2) to 356.9(2) pm, the center of the six-membered ring being 338.6(2) pm apart from that plane. Between the pairs, the closest π -system contact involves the above-mentioned anisole fragment and the indole fragment of a neighboring pair. The angle between the best planes of the sixmembered ring of the anisole fragment and the five-membered ring of the indole fragment is 12.8°. Individual distances of the atoms of the five-membered ring to the best plane of the sixmembered ring are in the range 340.1(2) to 371.5(3) pm, i.e., π - π -contacts within the pairs are significantly closer than between pairs.

Photophysical Properties. The photophysical properties of five selected 2-heteroaryl-substituted 3-ethynylquinoxalines **5** were thoroughly studied by UV/vis and fluorescence spectroscopy (Table 4). The structures were chosen as two consanguineous series to study the effects of the 2-substituent of the quinoxaline core (compounds **5a**, **5m**, **5r**) as well as the influence of the electronic nature of the aryl ethynyl group (compounds **5a**, **5d**, **5h**). Additionally, the emission solvatochromism of compound **5d** was investigated. The relative fluorescence quantum yields $\Phi_{\rm F}$ were determined with coumarin 153²⁹ as standard according to literature procedures.³⁰

In the UV/vis absorption spectra three to four distinct, broad, structureless maxima can be found, and the longest wavelength bands appear between $\lambda_{\rm max} = 418$ and 393 nm with molar absorption coefficients ε ranging from 8000 to 14600 L/mol·cm (Figure 2).

The remote arylethynyl substituent has only a minor effect on the position of this absorption band and varies from $\lambda_{max} =$ 408 (methoxy, compound **5d**) over 411 (hydrogen, compound **5a**) to 418 nm (cyano, compound **5h**). For the 2-substituent this effect is more pronounced. In the consanguineous series of compounds **5d**, **5m**, and **5r**, where the anisylethynyl substituent in 3-position is kept constant, the 1-methylindole (**5d**) and the 2-methoxythienyl (**5r**) derivative behave very similarly, whereas the more electron-rich 1-phenylpyrrolyl substituent of compound **5m** results in a blue shift of the longest wavelength absorption band to $\lambda_{max} = 393$ nm.

A similar picture emerges from the comparison of the emission spectra, where the structureless shortest wavelength emission band ranges between $\lambda_{max} = 474$ and 520 nm. By increasing the electron-withdrawing character of the remote arylethynyl substituent the emission maximum is red-shifted from $\lambda_{max} = 506$ (5d) over 510 (5a) to 520 nm (5h). While the position of the emission bands of 5d and 5r at 506 and 508 nm, respectively, are almost identical, the luminescence of the pyrrole derivative 5m is hypsochromically shifted to 474 nm. The Stokes shifts can be found in a narrow range between 4700 and 4800 cm⁻¹, except for the 1-phenyl pyrrole derivative 5m, which is with 4400 cm⁻¹ slightly smaller. The fluorescence quantum yields Φ_F of the 1-methylindole-substituted derivatives 5a, 5d, and 5h are hardly affected by the variation of the alkynyl substituent and lie between

0.15 and 0.18. However, compounds 5m and 5r display with 0.24 and 0.32 higher Φ_F values. More information on the

dipolar nature of the exited state was obtained by a solvatochromism study with the donor-substituted 1-methyl

Table 2. Glyoxylation-Alkynylation-Cyclocondensation Four-Component Synthesis of 2-Substituted 3-Ethynylquinoxalines 5

Entry ^[a]	R ¹ -H 1	Alkyne 2	1,2-Diaminoarene 4	3-Ethynylquinoxaline 5 (Yield) ^[b]
1	N-methylindole (1a)	$R^2 = Ph (2a)$	1,2-diaminobenzene (4a)	Ph N N
2	1a	$R^2 = SiMe_3$ (2b)	4 a	$ \begin{array}{c} \text{Me} \\ 5a (80\%) \\ \text{Me}_{5}Si \\ \downarrow \\ N \\ Me \\ 5b (79\%) \end{array} $
3	1a	$R^{2} = Si^{i}Pr_{3}$ (2c)	4 a	
4	1a	$R^2 = 4-$ MeOC ₆ H ₄ (2d)	4a	$ \begin{array}{c} & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & $
5	1a	$R^2 = 4$ - ^{<i>n</i>} BuC ₆ H ₄ (2e)	4a	5d (74%) "Bu (74%) "Bu (74%) "Bu (74%) "Bu (74%)
6	1a	$R^2 = 4-$ ^{<i>t</i>} BuC ₆ H ₄ (2f)	4a	5e (55%) ⁷ Bu V N N N N
7	1a	$R^{2} = 4-$ MeO ₂ CC ₆ H ₄ (2g)	4 a	5f (81%) MeO ₂ C , , , , , , , , , , , , , , , , , , ,
8	1a	$R^2 = 4$ - NCC ₆ H ₄ (2h)	4a	5g (85%)
9	1a	$R^2 = 4-FC_6H_4$ (2i)	4a	Sh (81%)
10	<i>N</i> -methylpyrrole (1b)	2ь	4a	$\begin{array}{c} \text{Si} (/0\%) \\ \text{Me}_3 \text{Si} \\ \text{Me} \\ \text{N} \\$
11	N-phenylpyrrole (1c)	2b	4a	5j (73%) Me _s si Ph N
12	1c	2a	4a	5k (75%)
13	1c	2d	4a	51 (73%) Meo Ph N N

5m (73%)

Table 2. continued

Entry ^[a]	R ¹ -H 1	Alkyne 2	1,2-Diaminoarene 4	3-Ethynylquinoxaline 5
		2		(Yield) ^[b]
14	1c	2h	4a	NC
				Ph
				N N N
15	N-	2b	4a	5n (68%) ™a3Si
	(triisopropylsilyl)pyrrole			
	(Id)			[/] Pr ₃ Si−N
16	2-methoxythiophene (1e)	2b	4a	50 (33%) Me ₃ Si
				Maga S N
				5p (59%)
17	1e	2a	4a	Ph
				MeO
				5q (28%)
18	1e	2d	4a	MeO
				s. L. L
				MeO () N (
19 ^[c]	azulene (1f)	2b	4 a	5F (35%) Me ₃ Si
				5s (62%)
20	1a	2b	1,2-diamino-4,5- dichlorobenzene (4b)	Me ₃ Si
			diemorobenzene (4b)	N CI
				N- Me E + (910/)
21	1 a	2b	1,2-diamino-4-	Me ₃ Si
			nitrobenzene (4c)	
				N-U Me
				5u (87%) ^[d]
22	1 a	2c	2,3-diaminopyridine (4d)	"Pr ₃ Si
			()	N N
				Me ⁽⁷
23	1a	2b	2,3-	Sv (12/0)
			diaminonaphthalene	
			(40)	N Me
24	1	2	<u>,</u>	5w (66%)
24	1a	Za	4e	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
				ме́ 5х (43%)

^{*a*}All compounds were prepared on a 2.00 mmol scale except for compounds **5i**, **5s**, and **5v**, which were prepared on a 1.00 mmol scale. ^{*b*}Yields after chromatography on silica gel. ^{*c*}For the synthesis **5s**, the glyoxylation step was carried out for 4 h at rt and the Stephens–Castro coupling was carried out for 15 h at rt. ^{*d*}Isomer ratio: 10:1, determined according to integrals in the ¹H NMR spectrum. ^{*e*}Isomer ratio: 6.5:1, determined according to integrals in the ¹H NMR spectrum.

Scheme 5. Consecutive Three-Component Synthesis of 3-Ethynylquinoxalines 7 through Activation–Alkynylation– Cyclocondensation Sequence



indole derivative **5d** in various solvents with solvent polarity $E_{\rm T}^{~\rm N}$ values ranging from 0.006 to 0.762 according to Reichardt's scale (Table 5).³¹

While the UV/vis absorption spectra display only a minor positive solvatochromism in the range from 405 to 415 nm, the influence of the solvent polarity on the emission band is quite significant and positive, ranging from 468 to 525 nm, i.e., $\Delta \tilde{\nu} = 2300 \text{ cm}^{-1}$ (Figure 3). This pronounced positive emission solvatochromism is additionally detectable upon eyesight, where the emission color changes from blue (cyclohexane) to orange (MeOH) (Figure 4).

The fluorescence quantum yield $\Phi_{\rm F}$ increases with decreasing solvent polarity, and the highest quantum yields $\Phi_{\rm F}$ were recorded in toluene (0.30). In protic solvents, such as alcohols, even lower values than for acetonitrile (0.13) were observed.

Table 5. Activation—Aikynylation—Cyclocondensation Three-Component Synthesis of 2-Substituted 5-Ethynylqunioxann	Table	3. Activation-	-Alkyn	vlation-	Cy	clocondensation	Three-	Com	ponent	Synt	hesis	of 2	-Sul	ostitute	ed 3	-Ethyn	vlquin	oxaline	ès
--	-------	----------------	--------	----------	----	-----------------	--------	-----	--------	------	-------	------	------	----------	------	--------	--------	---------	----

Entry ^[a]	Glyoxylic acid 6	3-Ethynylquinoxaline 7 (Yield) ^[b]
1	$\mathbf{R}^1 = \mathbf{Ph} \left(\mathbf{6a} \right)$	Me ₅ SI Ph N 7a (85 %)
2	$\mathbf{R}^{1} = \text{mesityl} (\mathbf{6b})$	Me ₃ Si N
		Me 7b (25 %)
3	$R^{1} = 2\text{-furyl} (6c)$	Me ₃ Si
4	$\mathbf{R}^1 = 2$ -thienyl (6d)	Me ₃ Si
		7d (69 %)

^{*a*}All compounds were prepared on a 2.00 mmol scale. ^{*b*}Yields after chromatography on silica gel.



Figure 1. Solid-state pair building of compound 5d (left) and crystal packing of compound 5d (right).

Table 4. UV/vis Absorption and Emission Data of Selected 2-Substituted 3-Ethynylquinoxalines 5

entry	absorption $\lambda_{\max,abs}$ (nm) (ε (M ⁻¹ cm ⁻¹)) ^a	emission $\lambda_{ ext{max,em}}/ ext{nm}~(\Phi_{ ext{F}})^{b,c}$	Stokes shift $\Delta \tilde{\nu}^d$ (cm ⁻¹)
5a	273 (31600), 287 (30400), 319 (25200), 411 (9900)	510 (0.16)	4700
5d	271 (37300), 303 (33900), 323 (28400), 337 (sh), 408 (13300)	506 (0.19)	4800
5h	277 (sh), 290 (41600), 328 (27200), 418 (8000)	520 (0.15)	4700
5m	266 (31300), 303 (31400), 337 (16300), 344 (sh), 393 (14600)	474 (0.24)	4400
5r	274 (21200), 312 (28400), 327 (sh), 343 (sh), 410 (11700)	508 (0.32)	4800
	· · · · · · · · · · · · · · · · · · ·		

^{*a*}Recorded in CH₂Cl₂, T = 293 K, $c(5) = 10^{-5}$ M. ^{*b*}Recorded in CH₂Cl₂, T = 293 K, $c(5) = 10^{-7}$ M. ^{*c*}Fluorescence quantum yields were recorded relative to coumarin 153 ($\Phi_F = 0.45$) as a standard in MeOH. ^{*d*} $\Delta \tilde{\nu} = 1/\lambda_{max,abs} - 1/\lambda_{max,abs}$.

A deactivation pathway from the excited state triggered by intermolecular solvent/solute hydrogen bonding appears to be a very likely explanation for this specific solvent effect.³²

Furthermore, the Lippert–Mataga equation allows a more quantitative treatment of the observed emission solvatochromism.³³ Large positive emission solvatochromism correlates with a considerable increase of the dipole moment on excitation.³⁴ Hence, the solvent-dependent Stokes shifts were plotted against the orientation polarizability Δf , which can be calculated according to

$$\Delta f = \frac{\varepsilon_r - 1}{2\varepsilon_r + 1} - \frac{n^2 - 1}{2n^2 + 1}$$

from the relative permittivity ε_r and the optical refractive index n of the solvent. The linear correlation displays an excellent goodness of fit ($r^2 = 0.92$), which indicates a dominant importance of a general solvent effect (Figure 5).³⁴

The change in dipole moment from the ground to the excited state can be calculated with the Lippert–Mataga equation

$$\tilde{\nu}_{a} - \tilde{\nu}_{f} = \frac{2\Delta f}{hca^{3}}(\mu_{E} - \mu_{G})^{2} + \text{const}$$

where $\tilde{\nu}_a$ and $\tilde{\nu}_f$ represent the absorption and emission maxima (in cm⁻¹), μ_E and μ_G are the dipole moment in the excited and ground state, h (6.6256 × 10⁻³⁴ Js) is Planck's constant, c (2.9979 × 10¹⁰ cm/s) is the speed of light, and a is the radius of the solvent cavity occupied by the molecule. Upon applying the Lippert–Mataga equation on charge-transfer compounds, typically, the Onsager radius is employed for a. This assumption is reasonable in cases, where the dipole moment is extended over a sticklike molecule.³⁴ However, the computations on compound **5d** revealed that the charge transfer only occurs between the indolyl substituent and the



Figure 2. UV/vis absorption^a (bold line) and emission spectrum^b (dashed line) of compound **5d**. (^aRecorded in CH₂Cl₂, T = 293 K, $c(5) = 10^{-5}$ M. ^bRecorded in CH₂Cl₂, T = 293 K, $c(5) = 10^{-7}$ M, $\lambda_{\text{excit.}} = 420$ nm.)

Table 5. Selected UV/vis Absorption and Emission Maxima of Compound 5d, Measured in Solvents of Different Polarity

solvent	absorption $\lambda_{ m max,abs}/ m nm$ $\left(arepsilon~(M^{-1} m cm^{-1}) ight)^a$	emission $\lambda_{ m max,em}/$ nm $(\Phi_{ m F})^{b,c}$	Stokes shift $\Delta \tilde{\nu}^d \ (\mathrm{cm}^{-1})$
toluene	407 (13300)	468 (0.30)	3200
THF	408 (13400)	490 (0.19)	4100
EtOAc	405 (14400)	491 (0.17)	4320
CH_2Cl_2	408 (13300)	506 (0.19)	4710
acetone	408 (14000)	513 (0.16)	5000
MeCN	407 (13200)	518 (0.13)	5300
ⁱ PrOH	415 (11700)	519 (0.02)	4800
EtOH	415 (12000)	522 (<0.01)	4900
MeOH	415 (12300)	525 (<0.01)	5100

^{*a*}Recorded in CH₂Cl₂, T = 293 K, $c(5) = 10^{-5}$ M. ^{*b*}Recorded in CH₂Cl₂, T = 293 K, $c(5) = 10^{-7}$ M. ^{*c*}Fluorescence quantum yields were recorded relative to coumarin 153 ($\Phi_{\rm F} = 0.45$) as a standard in MeOH. ^{*d*} $\Delta \tilde{\nu} = 1/\lambda_{\rm max,abs} - 1/\lambda_{\rm max,em}$.

(4-methoxyphenyl)ethynyl moiety, whereas the quinoxaline core, especially the benzo ring, is hardly involved. Therefore, employing the Onsager radius would not lead to reliable values for the transition dipole moment $\Delta \mu$. Nevertheless, with the computed values for $\Delta \mu$ (gas phase: 9.47 D, using Turbomole with the B3LYP functional and the def-TZVP basis set; CH₂Cl₂: relaxed 6.48 D, nonrelaxed 6.91 D, using Gaussian 09 with CAM-B3LYP functional and the 6-311G(d,p) basis set), we were able to calculate the dipole radii in the gas phase (0.51 nm) and in CH₂Cl₂ (relaxed 0.40 nm, nonrelaxed 0.42 nm). These results nicely match our estimated dipole radius (Figure 6).

Electronic Structure. A deeper rationalization of the observed photophysical behavior of the synthesized quinoxalines **5** was sought by elucidating the electronic structure by calculating UV/vis absorption spectra on the DFT level of theory, with special focus on the origin of the four longest wavelength absorption maxima of each structure. Therefore, first the geometries of the ground-state structures were optimized using Gaussian09³⁵ with the B3LYP functional³⁶ and the Pople 6-311G(d,p) basis set,³⁷ and the starting geometries obtained from X-ray structure analyses. Since all measurements were recorded in solution, the calculations were carried out using the polarizable continuum model (PCM) applying dichloromethane as solvent.³⁸ All minima structures were confirmed by analytical frequency analyses.

For the three different heteroaryl substituents in the 2-position of the quinoxaline moiety, the computations nicely match the equilibrium ground-state structures as obtained from X-ray structure analyses. For compounds **5m** and **5r**, the torsional angles between the quinoxaline plane and the heterocyclic ring in 2-position differ only slightly from the angles determined by X-ray of **5n** and **5q** (vide supra and Figure 7). In contrast, calculations suggest that the *N*-methylindole substituent of **5d** is twisted considerably more out of plane than it was found in the X-ray ($\theta_{calc} = 25^{\circ}$ vs $\theta_{X-ray} = 13^{\circ}$). Accordingly, the overlap and thereby the electronic communication in the case of thienyl and indolyl substituents is more efficient than that for the *N*-phenylpyrrole substituent.

The frontier molecular orbitals of the quinoxalines 5d, 5m, and 5r (Figure 8) show that for all three HOMOs the coefficient density is predominantly located on the quinoxaline and on the adjacent indolyl, pyrrolyl, and thienyl moiety, whereas the phenyl core of the pyrrole 5m does not possess any coefficient density. For the quinoxaline derivatives 5m (Figure 8, center) and



Figure 3. UV/vis absorption (solid lines) and emission spectra (dashed lines) of compound 5d, measured in nine solvents of different polarity (recorded at T = 293 K).



Figure 4. Emission solvatochromism of compound 5d (recorded in cyclohexane, toluene, THF, EtOAc, acetone, CH_2Cl_2 , MeCN, *i*PrOH, EtOH, MeOH (from left to right); T = 293 K; $c(5d) = 10^{-4}$ M; $\lambda_{excit} = 356$ nm, hand-held UV lamp).





Figure 7. Optimized geometries at the B3LYP 6-311G(d,p) level for the quinoxalines 5d, 5m, and 5r with different heteroaryl substituents in 2-position.



Figure 5. Lippert plot for compound **5d** $(n = 9, r^2 = 0.92)$.



Figure 6. Estimation of the dipolar radius *a* of compound 5d.

5r (Figure 8, right) the coefficients are also large both on the bridging triple bonds and the anisol cores, whereas only a neglectible coefficient density can be observed on the anisyl fragment of structure **5d**. In all three cases, the LUMOs do not bear any significant coefficient density on the heterocyclic substituents in 2-position of the quinoxaline. Here, the coefficients on the quinoxaline moieties are increased in comparison to the HOMOs, whereas the LUMO coefficients on the bridged triple bonds and the adjacent anisyl cores only show minor differences for structure **5d** (Figure 8, left) and a slightly diminished coefficient density for the other two structures. Already the computed ground-state structures indicate that HOMO–LUMO transitions should be accompanied with a dominant charge-transfer character from the heteroaryl substituents in 2-position to the central quinoxaline core.

The optimized structures of **5a**, **5d**, **5h**, **5m**, and **5r** were submitted to TD-DFT calculations to study the absorption characteristics (Table 6). The hybrid exchange-correlation functional CAM-B3LYP³⁹ was implemented and a non-equilibrium solvation⁴⁰ for the state-specific solvation of the vertical excitation was included. Expectedly, the longest

Figure 8. HOMOs (bottom) and LUMOs (top) of the quinoxalines 5d, 5m, and 5r.

wavelength absorption bands of all five computed molecules result from dominant contributions of the HOMO–LUMO transitions. The computed values are slightly hypsochromically shifted in comparison to the experimental data. The absorption maxima and shoulders appearing in the experimental UV/vis spectra at lower wavelength ranges were identified by comparing the oscillatory strength of the first 10 excitations of the first excited state. The computed values are in reasonably good agreement with the experimental data and major contributions of two more absorption maxima at lower wavelengths emanate predominantly from HOMO-1 \rightarrow LUMO, HOMO-1 \rightarrow LUMO+1, and HOMO \rightarrow LUMO+1 transitions. Only for structures **5h** and **5r** are other molecular orbitals involved.

CONCLUSION

The improved glyoxylation–Stephens–Castro coupling–cyclocondensation protocol represents an efficient and rapid access to 2-substituted 3-ethynylquinoxalines in the sense of a consecutive MCR. As a consequence of its diversity-oriented nature, large substance libraries are readily envisioned for

Table 6. TD-DFT Calculations (CAM-B3LYP 6-311G(d,p)) of the UV/vis Absorption Maxima of the Quinoxalines 5a, 5d, 5h, 5m, and 5r

structure	$\begin{array}{c}{\rm experimental}\; \lambda_{\max,{\rm abs}}{}^a\\ ({\rm nm})\end{array}$	computed $\lambda_{\max,abs}$ (nm) (most dominant contributions)				
5a	273	266 (HOMO-1 \rightarrow LUMO+1)				
	287	298 (HOMO-1 \rightarrow LUMO)				
	319	323 (HOMO \rightarrow LUMO+1)				
	411	371 (HOMO \rightarrow LUMO)				
5d	271	273 (HOMO-1 \rightarrow LUMO+1)				
	303	299 (HOMO \rightarrow LUMO+1)				
	323	330 (HOMO-1→ LUMO)				
	408	372 (HOMO \rightarrow LUMO)				
5h	277 (sh)	272 (HOMO-2 \rightarrow LUMO+1)				
	290	308 (HOMO-2 \rightarrow LUMO)				
	328	331 (HOMO \rightarrow LUMO+1)				
	418	383 (HOMO \rightarrow LUMO)				
5m	266	276 (HOMO-1 \rightarrow LUMO+1)				
	303	290 (HOMO \rightarrow LUMO+1)				
	337	327 (HOMO-1 \rightarrow LUMO)				
	393	364 (HOMO \rightarrow LUMO)				
5r	274	285 (HOMO-1 \rightarrow LUMO+1)				
	312	305 (HOMO-1 \rightarrow LUMO)				
	327 (sh)	319 (HOMO-4 \rightarrow LUMO)				
	343 (sh)	343 (HOMO \rightarrow LUMO+1)				
	410	373 (HOMO \rightarrow LUMO)				
^a Recorded in CH ₂ Cl ₂ , $T = 293$ K, $c(5) = 10^{-5}$ M.						

establishing experimentally founded structure–property relationships by variation of the individual components. Most interestingly, the title compounds display substantial emission solvatochromism and high quantum yields, as revealed by detailed photophysical studies and computations to rationalize the electronic structure. In addition, the ethynyl group is well suited for incorporation of these solvatochromic lumophores into more complex systems, most favorably as sensors for protein interactions.²⁶ Extended pluripotent functionalizations of 2-substituted 3-ethynylquinoxalines as well as their intriguing photophysics are currently under investigation.

EXPERIMENTAL SECTION

General Considerations. Reagents, catalysts, ligands, and solvents were purchased reagent grade and used without further purification. Anhydrous tetrahydrofuran, 1,4-dioxane, dichloromethane, and 1,2dichloroethane were obtained from a drying system. Triethylamine was refluxed under an argon atmosphere over sodium ketyl, distilled, and stored in a Schlenk flask under nitrogen atmosphere over potassium hydroxide pellets. Column chromatography: silica gel 60, mesh 70-230. TLC: silica gel plates 60 F254. All products were purified with column chromatography on silica gel 60 (0.040-0.063 mm) using flash technique under a pressure of 2 bar. The crude mixtures were absorbed on Celite 545 (0.02-0.10 mm) before chromatographic purification. The reaction progress was observed qualitatively using TLC silica gel 60 F₂₅₄ aluminum sheets. The spots were detected with UV light at 254 and 365 nm and with aqueous potassium permanganate solution. Chemical shifts δ in the ¹H NMR and ¹³C NMR spectra are reported in ppm relative to CDCl₃. The assignments of quaternary C, CH, CH₂, and CH₃ signals were made by using DEPT spectra.

General Procedure for the Three-Component Synthesis of 1-(1-Methyl-1*H*-indol-3-yl)-4-phenylbut-3-yne-1,2-dione (3a). A 268 mg (2.00 mmol) portion of 1a was placed under argon or nitrogen atmosphere in a screw-cap Schlenk tube with one of the listed solvents. The solution was degassed with argon/nitrogen. In the cases of THF, DCM, and DCE the solution was then cooled to 0 °C

(water/ice, 5 min). Then, oxalyl chloride (0.18 mL, 2.00 mmol, 1.0 equiv) was added dropwise to the reaction mixture. After being warmed to room temperature (water bath, 5 min), the reaction mixture was stirred for the indicated time at the indicated temperature (water bath/oil bath). If necessary, the mixture was then cooled to room temperature (water bath, 5 min). Then, CuI (20 mg, 0.1 mmol, 5 mol %), 1 equiv of phenylacetylene 2a (0.22 mL, 2.00 mmol, 1.0 equiv), and dry triethylamine (0.84 mL, 6.00 mmol, 3.0 equiv) were successively added to the reaction mixture, and stirring at room temperature was continued for the indicated time. 10 mL of water was added, the phases were separated, and the aqueous phase was extracted with dichloromethane $(3 \times 5 \text{ mL}/10 \text{ mL}, \text{ monitored by})$ TLC). The combined organic layers were dried with anhydrous sodium sulfate. After removal of the solvents in vacuo, the residue was absorbed onto Celite and purified chromatographically on silica gel with petroleum ether (boiling range 40-60 °C)/ethyl acetate (ratio 3:1) to give the ynedione 3a. Yellow solid. Mp: 128 °C. ¹H NMR (CDCl₃, 300 MHz): δ 3.86 (s, 3 H), 7.36-7.53 (m, 6 H), 7.68-7.74 (m, 2 H), 8.33 (s, 1 H), 8.44–8.52 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 33.8 (CH₃), 87.7 (C_{quat}), 97.5 (C_{quat}), 105.1 (CH), 110.0 (CH), 110.8 (C_{quat}), 111.0 (CH), 119.7 (C_{quat}), 122.7 (CH), 123.6 (CH), 124.2 (CH), 127.2 (C_{quat}), 128.6 (CH), 131.2 (CH), 133.6 (CH), 137.2 (C_{quat}), 140.2 (CH), 178.6 (C_{quat}), 180.1 (C_{quat}). EI + MS (m/z): 287 (M⁺, 2), 259 (C₁₈H₁₃NO⁺, 1), 231 (C₁₇H₁₃N⁺, 2), 158 $([M - C_9H_5O]^+, 100), 130 (C_9H_8N^+, 7), 129 (C_9H_5O^+), 103 (7), 97 (7), 77 (C_6H_5^+, 6), 57 (13). IR (solid): <math>\tilde{\nu}$ 3127 (w) [cm⁻¹], 2914 (w), 2853 (w), 2200 (m), 2156 (w), 1734 (w), 1643 (m), 1624 (m), 1578 (m), 1526 (m), 1464 (m), 1443 (m), 1377 (m), 1335 (w), 1281 (m), 1225 (m), 1171 (w), 1130 (m), 1074 (m), 1032 (m), 977 (m), 880 (m), 772 (m), 754 (m), 739 (s), 685 (s), 621 (m). Anal. Calcd for C19H13NO2 (287.3): C, 79.43; H, 4.56; N, 4.88. Found: C, 79.23; H, 4.76; N, 4.78.

General Procedure for the Four-Component Synthesis of 3-Ethynylchinoxalines 5. A 2.00 mmol portion of 1 in dry THF (2.5 mL/mmol) was placed under argon or nitrogen atmosphere in a sintered screw-cap Schlenk tube, degassed with argon or nitrogen, and cooled to 0 °C (water/ice, 5 min) (for experimental details see Table 7). Then, oxalyl chloride (0.18 mL, 2.00 mmol, 1.0 equiv) was added dropwise to the reaction mixture at 0 °C. The mixture was first warmed to room temperature (water bath, 5 min) and then stirred for 1 h at 50 °C (oil bath). Thereafter, the mixture was cooled to room temperature (water bath, 5 min). Then, CuI (20 mg, 0.1 mmol, 5 mol %), 1 equiv of terminal alkyne 2, and dry triethylamine (0.84 mL, 6.00 mmol, 3.0 equiv) were successively added to the reaction mixture, and stirring at room temperature was continued for 6 h. Then, 2 mL of methanol, 2.00 mmol of the 1,2-diaminoarene 4 (1.0 equiv), and 2 mL of acetic acid were added successively, the mixture was stirred at 50 °C for 1 h, 10 mL water was added, the phases were separated, and the aqueous phase was extracted with dichloromethane $(3 \times 5 \text{ mL}/10 \text{ mL}, \text{ monitored by TLC})$. The combined organic layers were dried with anhydrous sodium sulfate. After removal of the solvents in vacuo, the residue was absorbed onto Celite and purified chromatographically on silica gel with petroleum ether (boiling range 40-60 °C)/ethyl acetate to give the 3-ethinylchinoxalines 5.

2-(1-Methyl-1H-indol-3-yl)-3-(phenylethynyl)quinoxaline (5a). Yellow solid (574 mg, 80%). $R_f = 0.15$ (petroleum ether/ethyl acetate 7:1). Mp: 134 °C. ¹H NMR (CDCl₃, 300 MHz): δ 3.82 (s, 3 H), 7.22–7.29 (m, 2 H), 7.30–7.36 (m, 4 H), 7.50–7.55 (m, 2 H), 7.58 (ddd, J = 8.1 Hz, J = 4.8 Hz, J = 1.4 Hz, 1 H), 7.99 (ddd, J = 8.3 Hz, J = 6.9 Hz, J = 1.7 Hz, 1 H), 8.06 (dd, J = 8.2 Hz, J = 1.2 Hz, 1 H), 8.37 (s, 1 H), 8.64–8.71 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 33.4 (CH₃), 89.1 (C_{quat}), 94.1 (C_{quat}), 109.5 (CH), 112.4 (C_{quat}), 121.4 (CH), 122.0 (C_{quat}), 122.87 (CH), 122.93 (CH), 127.5 (C_{quat}), 130.4 (CH), 132.0 (CH), 132.5 (CH), 137.0 (C_{quat}), 137.3 (C_{quat}), 137.4 (C_{quat}), 141.1 (C_{quat}), 151.6 (C_{quat}). EI + MS (m/z): 360 (17), 359 (74), 358 (M⁺, 100), 344 ([M – CH₃]⁺, 9), 282 ([M – C₆H₅]⁺, 3), 180 (11), 172 (11), 158 (11), 156 (C₁₀H₈N₂⁺, 8). IR (solid): $\tilde{\nu}$ 3055 (w), 2955 (w), 2922 (w), 2853 (w), 2210 (w), 1337 (w), 1300 (w), 1281 (w), 1256 (w), 1236 (w), 1215 (m), 1178 (w), 1157 (w),

Table 7. Experimental Details for the Four-Component Synthesis of 2-Substituted 3-Ethynylquinoxalines 5

entry ^a	R ¹ -H 1	alkyne 2	1,2-diaminoarene 4	3-ethynyl- quinoxaline 5 (yield, %) b
1	268 mg (2.00 mmol) of 1a	0.18 mL (2.00 mmol) of 2a	216 mg (2.00 mmol) of 4a	574 mg (80%) of 5a
2	268 mg (2.00 mmol) of 1a	0.28 mL (2.00 mmol) of 2b	216 mg (2.00 mmol) of 4a	564 mg (79%) of 5b
3	268 mg (2.00 mmol) of 1a	0.45 mL (2.00 mmol) of 2c	216 mg (2.00 mmol) of 4a	749 mg (85%) of 5c
4	268 mg (2.00 mmol) of 1a	267 mg (2.00 mmol) of 2d	216 mg (2.00 mmol) of 4a	573 mg (74%) of 5d
5	268 mg (2.00 mmol) of 1a	0.36 mL (2.00 mmol) of 2e	216 mg (2.00 mmol) of 4a	455 mg (55%) of 5e
6	268 mg (2.00 mmol) of 1a	0.38 mL (2.00 mmol) of 2f	216 mg (2.00 mmol) of 4a	672 mg (81%) of 5f
7	268 mg (2.00 mmol) of 1a	320 mg (2.00 mmol) of (2g)	216 mg (2.00 mmol) of 4a	709 mg (85%) of 5g
8	268 mg (2.00 mmol) of 1a	262 mg (2.00 mmol) of 2h	216 mg (2.00 mmol) of 4a	623 mg (81%) of 5h
9	134 mg (1.00 mmol) of 1a	121 mg (1.00 mmol) of 2i	108 mg (1.00 mmol) of 4a	265 mg (70%) of 5i
10	164 mg (2.00 mmol) of 1b	0.28 mL (2.00 mmol) of 2b	216 mg (2.00 mmol) of 4a	446 mg (73%) of 5j
11	289 mg (2.00 mmol) of 1c	0.28 mL (2.00 mmol) of 2b	216 mg (2.00 mmol) of 4a	552 mg (75%) of 5k
12	289 mg (2.00 mmol) of 1c	0.18 mL (2.00 mmol) of 2a	216 mg (2.00 mmol) of 4a	544 mg (73%) of 51
13	289 mg (2.00 mmol) of 1c	267 mg (2.00 mmol) of 2d	216 mg (2.00 mmol) of 4a	589 mg (73%) of 5m
14	289 mg (2.00 mmol) of 1c	262 mg (2.00 mmol) of 2h	216 mg (2.00 mmol) of 4a	536 mg (68%) of 5n
15	446 mg (2.00 mmol) of 1d	0.28 mL (2.00 mmol) of 2b	216 mg (2.00 mmol) of 4a	496 mg (55%) of 50
16	470 mg (2.00 mmol) of 1e	0.28 mL (2.00 mmol) of 2b	216 mg (2.00 mmol) of 4a	398 mg (59%) of 5p
17	470 mg (2.00 mmol) of 1e	0.18 mL (2.00 mmol) of 2a	216 mg (2.00 mmol) of 4a	192 mg (28%) of 5q
18	470 mg (2.00 mmol) of 1e	267 mg (2.00 mmol) of 2d	216 mg (2.00 mmol) of 4a	243 mg (33%) of 5r
19 ^c	128 mg (1.00 mmol) of 1f	0.14 mL (1.00 mmol) of 2b	108 mg (1.00 mmol) of 4a	437 mg (62%) of 5s
20	268 mg (2.00 mmol) of 1a	0.28 mL (2.00 mmol) of 2b	361 mg (2.00 mmol) of (4b)	686 mg (81%) of 5t
21	268 mg (2.00 mmol) of 1a	0.28 mL (2.00 mmol) of 2b	313 mg (2.00 mmol) of 4c	694 mg (87%) of $5\mathbf{u}^d$
22	134 mg (1.00 mmol) of 1a	0.23 mL (1.00 mmol) of 2c	107 mg (1.00 mmol) of 4d	358 mg (72%) of $5v^e$
23	268 mg (2.00 mmol) of 1a	0.28 mL (2.00 mmol) of 2b	326 mg (2.00 mmol) of 4e	537 mg (66%) of 5w
24	268 mg (2.00 mmol) of 1a	0.18 mL (2.00 mmol) of 2a	326 mg (2.00 mmol) of 4e	349 mg (43%) of 5x

^{*a*}All compounds were prepared on a 2.00 mmol scale except for compounds **5i**, **5s**, and **5v**, which were prepared on a 1.00 mmol scale. ^{*b*}Yields after chromatography on silica gel. ^{*c*}For the synthesis **5s**, the glyoxylation step was carried out for 4 h at rt and the Stephens–Castro coupling was carried out for 15 h at rt. ^{*d*}Isomer ratio: 10:1, determined according to integrals in the ¹H NMR spectrum. ^{*e*}Isomer ratio: 6.5:1, determined according to integrals in the ¹H NMR spectrum.

1128 (m), 1111 (m), 1082 (m), 1011 (w), 937 (m), 905 (w), 839 (w), 827 (w), 740 (s), 681 (s), 656 (w), 640 (w), 611 (m). Anal. Calcd for $C_{25}H_{17}N_3$ (359.4): C, 83.59; H, 4.77; N, 11.69. Found: C, 83.50; H, 4.89; N, 11.40.

2-(1-Methyl-1H-indol-3-yl)-3-[(trimethylsilyl)ethynyl]quinoxaline (5b). Yellow solid (564 mg, 79%). $R_f = 0.32$ (petroleum ether/ethyl acetate 7:1). Mp: 160 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.37 (s, 9 H), 3.91 (s, 3 H), 7.30-7.44 (m, 3 H), 7.65 (ddd, J = 8.3 Hz, J = 6.9 Hz, J = 1.4 Hz, 1 H), 7.73 (ddd, J = 8.3 Hz, J = 6.9 Hz, J = 1.5 Hz, 1 H), 8.04 (dd, J = 8.3 Hz, J = 1.5 Hz, 1 H), 8.12 (dd, J = 8.3 Hz, J = 1.5 Hz, 1 H), 8.58 (s, 1 H), 8.78-8.81 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ -0.5 (CH₃), 33.3 (CH₃), 100.9 (C_{quat}), 104.4 (C_{quat}), 109.4 (CH), 112.0 (C_{quat}), 121.5 (CH), 122.9 (CH), 123.1 (CH), 127.5 (C_{quat}), 128.57 (CH), 128.63 (CH), 128.7 (CH), 130.6 (CH), 132.8 (CH), 136.3 (C_{quat}), 137.2 (C_{quat}), 139.1 (C_{quat}), 141.1 (C_{quat}), 150.4 (C_{quat}). EI + MS (m/z): 356 (29), 355 (M^+ , 100), 354 (45), 341 (15), 340 ($[M - CH_3]^+$, 52), 325 ($[M - (CH_3)_2]^+$, 7), 310 ([M - $(CH_3)_3]^+$, 10), 282 ($[M - C_3H_9Si]^+$, 11), 156 ($C_{10}H_8N_2$, 10), 157 (18). IR (solid): $\tilde{\nu}$ 3065 (w), 2966 (w), 2160 (w), 1612 (w), 1531 (m), 1477 (w), 1454 (w), 1422 (w), 1369 (w), 1344 (w), 1337 (w), 1287 (m), 1248 (m), 1240 (m), 1215 (m), 1198 (w), 1161 (w), 1119 (m), 1082 (m), 1047 (w), 1013 (w), 935 (m), 914 (w), 841 (s), 758 (w), 727 (s), 700 (w), 646 (w), 633 (m), 615 (w). Anal. Calcd for C22H21N3Si (355.5): C, 74.33; H, 5.95; N, 11.82. Found: C, 74.13; H, 5.76; N, 11.91.

2-(1-Methyl-1H-indol-3-yl)-3-[(triisopropylsilyl)ethynyl]quinoxaline (5c). Yellow solid (749 mg, 85%). $R_f = 0.47$ (petroleum ether/ethyl acetate 6:1). Mp: 100 °C. ¹H NMR (CDCl₃, 300 MHz): δ 1.12–1.29 (m, 21 H), 3.88 (s, 3 H), 7.30–7.43 (m, 3 H), 7.64 (ddd, J = 8.3 Hz, J = 6.9 Hz, J = 1.6 Hz, 1 H), 7.72 (ddd, J = 8.4 Hz, J = 6.9Hz, J = 1.6 Hz, 1 H), 8.04 (dd, J = 8.3 Hz, J = 1.4 Hz, 1 H), 8.11 (dd, J = 8.3 Hz, J = 1.4 Hz, 1 H), 8.59 (s, 1 H), 8.73–8.80 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 11.4 (CH), 18.7 (CH₃), 33.2 (CH₃), 97.6 (C_{quat}), 106.4 (C_{quat}), 109.4 (CH), 112.2 (C_{quat}), 121.4 (CH), 122.9 (CH), 123.0 (CH), 127.5 (C_{quat}), 128.5 (CH), 128.6 (CH), 128.7 (CH), 130.4 (CH), 132.6 (CH), 136.7 (C_{quat}), 137.3 (C_{quat}), 139.4 (C_{quat}), 141.0 (C_{quat}), 150.4 (C_{quat}). EI + MS (*m*/*z*): 440 (35), 439 (M⁺, 100), 397 (24), 396 ([M - C₃H₇]⁺, 70), 368 (11), 354 (26), 353 ([M - (C₃H₇)₂]⁺, 6), 339 (11), 338 (10), 326 (20), 312 (12), 311 (21), 310 ([M - (C₃H₇)₃]⁺, 33), 296 (13), 167 (12), 162 (12), 156 (12), 155 (11), 154 (10), 149 (17). IR (solid): $\tilde{\nu}$ 2945 (w), 2864 (w), 1537 (m), 1526 (m), 1452 (m), 1423 (w), 1383 (m), 1371 (m), 1339 (w), 1310 (w), 1287 (w), 1242 (w), 1217 (m), 1200 (m), 1159 (w), 1142 (w), 1125 (w), 1084 (m), 1013 (w), 995 (w), 935 (m), 880 (m), 758 (m), 745 (s), 681 (s), 658 (m), 615 (m). Anal. Calcd for C₂₈H₃₃N₃Si (439.7): C, 76.49; H, 7.57; N, 9.56. Found: C, 76.68; H, 7.69; N, 9.42.

2-[(4-Methoxyphenyl)ethynyl]-3-(1-methyl-1H-indol-3-yl)*quinoxaline* (5d). Yellow solid (573 mg, 74%). $R_f = 0.33$ (dichloromethane). Mp: 164 °C. ¹H NMR (CDCl₃, 300 MHz): δ 3.77 (s, 3 H), 3.83 (s, 3 H), 6.79-6.93 (m, 2 H), 7.20-7.39 (m, 3 H), 7.41-7.51 (m, 2 H), 7.55-7.68 (m, 2 H), 7.99 (dd, J = 8.2 Hz, J = 1.4 Hz, 1 H), 8.05 (dd, J = 8.2 Hz, J = 1.2 Hz, 1 H), 8.38 (s, 1 H), 8.63-8.71 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 33.4 (CH₃), 55.4 (CH_3) , 88.7 (C_{quat}) , 94.9 (C_{quat}) , 109.4 (CH), 112.4 (C_{quat}) , 113.9 (C_{ouat}), 114.3 (CH), 121.4 (CH), 123.0 (CH), 127.5 (C_{quat}), 128.4 (CH), 128.6 (CH), 128.8 (CH), 130.2 (CH), 132.6 (CH), 133.7 (CH), 137.4 (C_{quat}) 139.4 (C_{quat}), 140.8 (C_{quat}), 150.5 (C_{quat}), 160.7 (C_{quat}). EI + MS (m/z):. 390 (26), 389 (M⁺, 100), 388 (94), 374 $([M - CH_3]^+, 21), 358 ([M-OCH_3]^+, 6), 346 (15), 345 (21), 282$ $(C_{19}H_{12}N_3^+, 4)$, 232 $(C_{16}H_{12}N_2^+, 4)$, 231 (13), 195 (11), 190 (11), 173 (14), 172 (16), 156 (11), 155 (11). IR (solid): $\tilde{\nu}$ 3044 (w), 2967 (w), 2901 (w), 2197 (w), 1605 (w), 1539 (m), 1508 (m), 1454 (m), 1371 (w), 1292 (w), 1254 (m), 1236 (w), 1211 (w), 1167 (w), 1155 (w), 1125 (m), 1113 (m), 1082 (m), 1032 (m), 1011 (m), 937 (m), 822 (s), 795 (w), 756 (m), 741 (s), 625 (m). Anal. Calcd for C₂₆H₁₉N₃O (389.5): C, 80.18; H, 4.92; N, 10.79. Found: C, 80.00; H, 4.88; N, 10.68.

2-[(4-Butylphenyl)ethynyl]-3-(1-methyl-1H-indol-3-yl)quinoxaline (5e). Yellow solid (455 mg, 55%). $R_f = 0.48$ (dichloromethane). Mp: 129 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.95 (t, J = 7.3 Hz, 3 H), 1.38 (sext, J = 7.3 Hz, 2 H), 1.57-1.69 (m, 2 H), 2.65 (t, J = 7.7 Hz, 2 H),3.91 (s, 3 H), 7.20-7.25 (m, 2 H), 7.30-7.44 (m, 3 H), 7.50-7.56 (m, 2 H), 7.66 (ddd, J = 8.4 Hz, J = 6.9 Hz, J = 1.6 Hz, 1 H), 7.73 (ddd, I = 8.3 Hz, I = 6.9 Hz, I = 1.7 Hz, 1 H), 8.03-8.11 (m, 1 H),8.10-8.17 (m, 1 H), 8.48 (s, 1 H), 8.73-8.81 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 13.9 (CH₃), 22.3 (CH₂), 33.3 (CH₂), 33.4 (CH₃), 35.7 (CH₂), 89.2 (C_{quat}), 94.7 (C_{quat}), 109.4 (CH), 112.3 (C_{ouat}), 119.0 (C_{ouat}), 121.4 (CH), 122.9 (CH), 127.5 (C_{ouat}), 128.5 (CH), 128.6 (CH), 128.8 (CH), 130.3 (CH), 131.9 (CH), 132.6 (CH), 137.1 (C_{quat}), 137.3 (C_{quat}), 139.3 (C_{quat}), 140.9 (C_{quat}), 145.0 (C_{quat}) , 150.6 (C_{quat}) . MALDI-MS: $m/z = 416.1 \text{ [MH^+]}$. IR (solid): $\tilde{\nu}$ 3100 (w), 3040 (w), 2959 (w), 2930 (w), 2899 (w), 2859 (w), 2311 (w), 2203 (w), 1528 (m), 1508 (m), 1474 (w), 1456 (w), 1423 (w), 1402 (w), 1368 (m), 1352 (w), 1339 (m), 1329 (w), 1296 (w), 1277 (w), 1256 (w), 1234 (w), 1211 (m), 1171 (w), 1153 (w), 1126 (m), 1113 (m), 1080 (m), 1047 (w), 1015 (m), 988 (w), 935 (m), 908 (w), 881 (w), 826 (m), 812 (w), 783 (w), 756 (s), 739 (s), 642 (w), 610 (m). Anal. Calcd for C₂₉H₂₅N₃ (415.5): C, 83.82; H, 6.06; N, 10.11. Found: C, 83.58; H, 6.28; N, 10.09.

2-[(4-tert-Butylphenyl)ethynyl]-3-(1-methyl-1H-indol-3-yl)quinoxaline (5f). Yellow solid (672 mg, 81%). $R_f = 0.24$ (petroleum ether/ethyl acetate 8:1). Mp: 130 °C. ¹H NMR (\dot{CDCl}_3 , 300 MHz): δ 1.36 (s, 9 H), 3.92 (s, 3 H), 7.31-7.39 (m, 2 H), 7.40-7.47 (m, 3 H), 7.54-7.59 (m, 2 H), 7.67 (ddd, I = 8.2 Hz, I = 6.8 Hz, I = 1.6 Hz, 1 H), 7.73 (ddd, J = 8.2 Hz, J = 6.8 Hz, J = 1.7 Hz, 1 H), 8.07 (dd, J =11), 7.75 (ddd, J = 0.2 112, J = 0.0 112, J = 1.7 112, J = 1.7 11), 6.07 (dd, J = 8.1 Hz, J = 1.3 Hz, 1 H), 8.14 (dd, J = 8.2 Hz, J = 1.2 Hz, 1 H), 8.49 (s, 1 H), 8.74–8.81 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 31.1 (CH₃), 33.5 (CH₃), 35.0 (C_{quat}), 89.2 (C_{quat}), 94.6 (C_{quat}), 109.4 (CH), 112.4 (C_{quat}), 118.9 (C_{quat}), 121.4 (CH), 122.9 (CH), 125.7 (CH), 127.5 (C_{quat}), 128.5 (CH), 128.6 (CH), 128.7 (CH), 129.2 (CH), 127.2 (CH), 12 130.3 (CH), 131.8 (CH), 132.6 (CH), 137.2 (C_{quat}), 137.3 (C_{quat}), 139.3 (C_{quat}), 140.9 (C_{quat}), 150.6 (C_{quat}), 153.1 (\dot{C}_{quat}). MALDI-MS: $m/z = 416 \text{ [MH^+]}$. IR (solid): $\tilde{\nu}$ 3048 (w), 3030 (w), 2957 (w), 2930 (w), 2909 (w), 2866 (w), 2853 (w), 2376 (w), 2205 (w), 1533 (s), 1518 (m), 1506 (m), 1477 (w), 1452 (w), 1425 (w), 1371 (m), 1298 (w), 1236 (w), 1215 (m), 1130 (w), 1101 (m), 1082 (w), 1013 (w), 935 (m), 908 (w), 835 (w), 758 (m), 743 (s), 694 (w), 638 (w), 615 (m). Anal. Calcd for C₂₉H₂₅N₃ (415.5): C, 83.82; H, 6.06; N, 10.11. Found: C, 83.71; H, 5.95; N, 9.89.

2-[(4-Methoxycarbonylphenyl)ethynyl]-3-(1-methyl-1H-indol-3yl)quinoxaline (5g). Yellow solid (709 mg, 85%). $R_f = 0.14$ (dichloromethane). Mp: 182 °C. ¹H NMR (CDCl₃, 300 MHz): δ 3.88 (s, 3 H), 3.94 (s, 3 H), 7.30-7.39 (m, 2 H), 7.39-7.44 (m, 1 H), 7.58-7.64 (m, 2 H), 7.67 (ddd, J = 8.3 Hz, J = 6.9 Hz, J = 1.5 Hz, 1 H), 7.74 (ddd, J = 8.4 Hz, J = 6.9 Hz, J = 1.6 Hz, 1 H), 8.02–8.19 (m, 3 H), 8.11-8.16 (m, 1 H), 8.35 (s, 1 H), 8.67-8.75 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 33.4 (CH₃), 52.3 (CH₃), 92.0 (C_{nut}), 92.7 (C_{quat}), 109.5 (CH), 112.3 (C_{quat}), 121.4 (CH), 122.8 (CH), 123.0 (CH), 126.4 (C_{quat}), 127.3 (C_{quat}), 128.6 (CH), 128.7 (CH), 128.9 (CH), 129.7 (CH), 130.6 (C_{quat}), 130.7 (CH), 131.8 (CH), 132.3 (CH), 136.5 (C_{quat}), 137.3 (C_{quat}), 139.4 (C_{quat}), 141.2 (C_{quat}), 150.6 (C_{quat}), 166.2 (C_{quat}). MALDI-MS: m/z = 418 [MH⁺]. IR (solid): $\tilde{\nu}$ 3649 (w), 3127 (w), 3046 (w), 3019 (w), 2992 (w), 2945 (w), 2913 (w), 2874 (w), 2835 (w), 2313 (w), 2205 (w), 1719 (s), 1603 (w), 1539 (m), 1506 (w), 1474 (w), 1454 (w), 1429 (w), 1402 (w), 1369 (w), 1339 (w), 1271 (m), 1236 (m), 1217 (m), 1171 (m), 1132 (m), 1101 (m), 1082 (m), 1049 (w), 1015 (m), 935 (m), 907 (w), 847 (w), 816 (w), 748 (s), 687 (m), 646 (w), 615 (m). Anal. Calcd for C₂₇H₁₉N₃O₂ (417.5): C, 77.68; H, 4.59; N, 10.07. Found: C, 77.54; H, 4.70; N, 9.90.

2-[(4-Cyanophenyl)ethynyl]-3-(1-methyl-1H-indol-3-yl)quinoxaline (**5h**). Yellow solid (623 mg, 81%). $R_f = 0.12$ (dichloromethane). Mp: 245 °C. ¹H NMR (CDCl₃, 300 MHz): δ 3.91 (s, 3 H), 7.35 (tdd, J = 8.4 Hz, J = 7.0 Hz, J = 1.6 Hz, 2 H), 7.41– 7.46 (m, 1 H), 7.60 (m 2 H), 7.67 (m, 2 H), 7.70 (ddd, J = 8.5 Hz, J =6.9 Hz, J = 1.6 Hz, 1 H), 7.78 (ddd, J = 8.4 Hz, J = 7.0 Hz, J = 1.6 Hz, 1 H), 8.07 (dd, J = 8.2 Hz, J = 1.2 Hz, 1 H), 8.15 (dd, J = 8.2 Hz, $\begin{array}{l} J = 1.1 \ \mathrm{Hz}, 1 \ \mathrm{H}), \ 8.25 \ (\mathrm{s}, 1 \ \mathrm{H}), \ 8.59-8.68 \ (\mathrm{m}, 1 \ \mathrm{H}). \ ^{13}\mathrm{C} \ \mathrm{NMR} \\ (\mathrm{CDCl}_3, \ 75 \ \mathrm{MHz}): \ \delta \ 33.5 \ (\mathrm{CH}_3), \ 91.5 \ (\mathrm{C}_{\mathrm{quat}}), \ 93.1 \ (\mathrm{C}_{\mathrm{quat}}), \ 109.6 \\ (\mathrm{CH}), \ 112.4 \ (\mathrm{C}_{\mathrm{quat}}), \ 112.8 \ (\mathrm{C}_{\mathrm{quat}}), \ 118.1 \ (\mathrm{C}_{\mathrm{quat}}), \ 121.5 \ (\mathrm{CH}), \ 122.6 \\ (\mathrm{CH}), \ 123.1 \ (\mathrm{CH}), \ 126.7 \ (\mathrm{C}_{\mathrm{quat}}), \ 127.2 \ (\mathrm{C}_{\mathrm{quat}}), \ 128.7 \ (\mathrm{CH}), \ 128.8 \\ (\mathrm{CH}), \ 129.2 \ (\mathrm{CH}), \ 131.1 \ (\mathrm{CH}), \ 132.1 \ (\mathrm{CH}), \ 132.2 \ (\mathrm{CH}), \ 132.4 \\ (\mathrm{CH}), \ 136.2 \ (\mathrm{C}_{\mathrm{quat}}), \ 137.3 \ (\mathrm{C}_{\mathrm{quat}}), \ 139.5 \ (\mathrm{C}_{\mathrm{quat}}), \ 141.3 \ (\mathrm{C}_{\mathrm{quat}}), \ 150.7 \\ (\mathrm{C}_{\mathrm{quat}}). \ \mathrm{MALDI-MS:} \ m/z = 385 \ [\mathrm{MH^+}]. \ \mathrm{IR} \ (\mathrm{solid}): \ \tilde{\nu} \ 3649 \ (\mathrm{w}), \ 3123 \\ (\mathrm{w}), \ 3046 \ (\mathrm{w}), \ 2907 \ (\mathrm{w}), \ 2369 \ (\mathrm{w}), \ 2224 \ (\mathrm{w}), \ 1601 \ (\mathrm{w}), \ 1541 \ \mathrm{m}), \\ 1535 \ (\mathrm{m}), \ 1499 \ (\mathrm{w}), \ 1476 \ (\mathrm{w}), \ 1456 \ (\mathrm{m}), \ 1423 \ (\mathrm{w}), \ 1404 \ (\mathrm{w}), \ 1371 \\ (\mathrm{m}), \ 1352 \ (\mathrm{w}), \ 1339 \ (\mathrm{w}), \ 1300 \ (\mathrm{w}), \ 1256 \ (\mathrm{w}), \ 1236 \ (\mathrm{w}), \ 2111 \ \mathrm{m}), \\ 1130 \ (\mathrm{m}), \ 1111 \ (\mathrm{m}), \ 1082 \ (\mathrm{m}), \ 0111 \ (\mathrm{w}), \ 937 \ (\mathrm{m}), \ 908 \ (\mathrm{w}), \ 837 \ (\mathrm{w}), \\ 822 \ (\mathrm{w}), \ 768 \ (\mathrm{s}), \ 739 \ (\mathrm{s}), \ 646 \ (\mathrm{w}), \ 619 \ (\mathrm{w}). \ \mathrm{Anal. Calcd \ for \ } C_{26}\mathrm{H}_{16}\mathrm{H}_4 \\ (\ 384.4): \ \mathrm{C}, \ 81.23; \ \mathrm{H}, \ 4.20; \ \mathrm{N}, \ 14.57. \ \mathrm{Found:} \ \mathrm{C}, \ \ 81.28; \ \mathrm{H}, \ 4.04; \ \mathrm{N}, \\ 14.33. \end{array}$

2-[(4-Fluorophenyl)ethynyl]-3-(1-methyl-1H-indol-3-yl)quinoxaline (5i). Yellow solid (265 mg, 70%). $R_f = 0.33$ (dichloromethane). Mp: 176 °C. ¹H NMR (CDCl₃, 300 MHz): δ 3.88 (s, 3 H), 7.05-7.15 (m, 2 H), 7.29-7.45 (m, 3 H), 7.52-7.60 (m, 2 H), 7.68 (dd, J = 6.9 Hz, J = 1.5 Hz, 1 H), 7.73 (dd, J = 6.8 Hz, J = 1.5 Hz, 1 H), 8.06 (dd, J = 8.2 Hz, J = 1.3 Hz, 1 H), 8.13 (dd, J = 8.3 Hz, J = 1.1 Hz, 1 H), 8.36 (s, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 33.4 (CH₃), 89.4 (C_{quat}), 92.9 (C_{quat}), 109.5 (CH), 112.4 (C_{quat}), 116.0 (d, J = 22.2Hz, CH), 118.1 (d, J = 3.5 Hz, C_{quat}), 121.4 (CH), 122.8 (CH), 122.9 (CH), 127.4 (C_{quat}), 128.6 (CH), 128.7 (CH), 128.8 (CH), 130.5 (CH), 132.3 (CH), 134.0 (d, J = 8.6 Hz, CH), 136.9 (C_{quat}), 137.3 (C_{quat}) , 139.4 (C_{quat}) , 141.1 (C_{quat}) , 150.6 (C_{quat}) 163.2 $(d, J = 251.9 Hz, C_{quat})$. EI + MS (m/z):. 377 $(M^+, 100)$, 376 (20), 159 (13), 158 (100). IR (solid): $\tilde{\nu}$ 3044 (w), 2361 (w), 2201 (w), 1599 (w), 1533 (m), 1504 (m), 1476 (w), 1452 (w), 1404 (w), 1381 (w), 1356 (m), 1339 (w), 1298 (w), 1229 (m), 1213 (m), 1177 (w), 1150 (w), 1132 (w), 1111 (m), 1078 (w), 1013 (w), 935 (w), 822 (m), 797 (w), 748 (s), 621 (w), 619 (w). Anal. Calcd for C₂₅H₁₆FN₃ (377.4): C, 79.56; H. 4.27: N. 11.13. Found: C. 79.37: H. 4.40; N. 10.93.

2-(1-Methyl-1H-pyrrol-2-yl)-3-[(trimethylsilyl)ethynyl]quinoxaline (5). Brownish solid (446 mg, 73%). $R_f = 0.88$ (dichloromethane). Mp: 53 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.31 (s, 9 H), 4.00 (s, 3 H), 6.24 (dd, J = 4.0 Hz, J = 2.6 Hz, 1 H), 6.84–6.87 (m, 1 H), 7.38 (dd, J = 4.0 Hz, J = 1.7 Hz, 1 H), 7.62–7.68 (m, 1 H), 7.68–7.73 (m, 1 H), 7.94–7.97 (m, 1 H), 8.01–8.05 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ -0.6 (CH₃), 37.1 (CH₃), 101.6 (CH), 103.3 (C_{quat}), 107.4 (C_{quat}), 116.3 (CH), 128.1 (CH), 128.2 (C_{quat}), 128.5 (CH), 128.8 (CH), 129.2 (CH), 130.6 (CH), 137.2 (C_{quat}), 139.3 (C_{quat}), 140.1 (C_{quat}), 147.6 (C_{quat}). MALDI-MS: m/z = 306.4 [MH⁺]. IR (solid): $\tilde{\nu}$ 3067 (w), 2959 (w), 2845 (w), 2488 (w), 1541 (m), 1520 (w), 1489 (w), 1472 (w), 1450 (w), 1422 (m), 1400 (w), 1369 (w), 1337 (w), 1312 (w), 1277 (w), 1252 (w), 1227 (w), 1215 (w), 1184 (m), 1134 (w), 1123 (w), 1098 (w), 1065 (m), 980 (m), 959 (w), 912 (w), 878 (w), 843 (s), 810 (m), 760 (s), 739 (s), 692 (m), 658 (w), 631 (m), 606 (m). Anal. Calcd for C₁₈H₁₉N₃Si (305.5): C, 70.78; H, 6.27; N, 13.76. Found: C, 70.89; H, 6.28; N, 13.77.

2-(1-Phenyl-1H-pyrrol-3-yl)-3-[(trimethylsilyl)ethynyl]quinoxaline (5k). Yellow resin (552 mg, 75%). $R_f = 0.24$ (petroleum ether/ethyl acetate 20:1). ¹H NMR (CDCl₃, 300 MHz): δ 0.31 (s, 9 H), 6.44 (dd, J = 3.8 Hz, J = 2.8 Hz, 1 H), 7.11 (dd, J = 2.7 Hz, J = 1.7 Hz, 1 H), 7.14-7.19 (m, 2 H), 7.21-7.28 (m, 3 H), 7.32 (dd, J = 3.8 Hz, J = 1.7 Hz, 1 H), 7.50-7.65 (m, 3 H), 7.96-8.02 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ –0.5 (CH₃), 101.8 (C_{quat}), 102.5 (C_{quat}), 109.3 (CH), 116.6 (CH), 125.4 (CH), 126.4 (CH), 127.0 (CH), 128.6 (CH), 128.66 (C_{quat}), 128.71 (CH), 129.6 (CH), 130.5 (CH), 137.6 (C_{quat}) , 139.6 (C_{quat}) , 140.0 (C_{quat}) 141.1 (C_{quat}) , 147.5 (C_{quat}) . EI + MS (m/z): 368 (14), 367 $(M^+, 47)$, 366 (24), 353 (11), 337 $([M - M^+])$ CH_3]⁺, 38), 326 (10), 294 ([M - [Si(CH_3)_3]⁺, 5), 290 ([M - (C_5H_6)], 12), 243 (13), 149 (17), 101 (11), 59 (23), 58 (11); 57 (17), 56 (19), 55 (13), 43 (100), 41 (18). IR (solid): $\tilde{\nu}$ 2957 (w), 1597 (w), 1541 (w), 1520 (w), 1499 (m), 1470 (w), 1456 (w), 1425 (m), 1391 (w), 1354 (w), 1327 (w), 1306 (w), 1281 (w), 1250 (w), 1229 (w), 1207 (m), 1182 (w), 1132 (m), 1123 (m), 1074 (w), 947 (m), 910 (w), 885 (w), 841 (s), 810 (m), 797 (w), 758 (s), 725 (s), 696 (s), 663 (m), 631 (m), 613 (m). Anal. Calcd for C₂₃H₂₁N₃Si (367.5): C, 75.17; H, 5.76; N, 11.43. Found: C, 75.10; H, 5.81; N, 11.32.

2-(1-Phenyl-1H-pyrrol-2-yl)-3-(phenylethynyl)quinoxaline (5l). Yellow solid (544 mg, 73%). $R_f = 0.53$ (dichloromethane). Mp: 109 °C. ¹H NMR (CDCl₃, 300 MHz): δ 6.51 (dd, J = 3.8 Hz, J = 2.8 Hz, 1 H), 7.12–7.19 (m, 3 H), 7.19–7.25 (m, 2 H), 7.30 (dd, J = 3.8 Hz, I = 1.7 Hz, 1 H), 7.37 - 7.44 (m, 3 H), 7.57 - 7.64 (m, 4 H), 7.65 - 7.647.70 (m, 1 H), 7.99–8.05 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 88.0 (C_{quat}), 94.9 (C_{quat}), 109.6 (CH), 116.2 (CH), 121.8 (C_{quat}), 125.2 (CH), 126.4 (CH), 126.6 (CH), 128.45 (CH), 128.52 (CH), 128.78 (CH), 128.81 (CH), 129.1 (C_{quat}), 129.5 (CH), 129.7 (CH), 130.4 (CH), 132.3 (CH), 138.3 (C_{quat}), 139.9 (C_{quat}), 140.1 (C_{quat}), 140.9 (C_{quat}), 148.0 (C_{quat}). MALDI-MS: m/z = 372 [MH⁺]. IR (solid): $\tilde{\nu}$ 3647 (w), 3057 (w), 2360 (w), 2330 (w), 2210 (w), 1989 (w), 1965 (w), 1597 (w), 1541 (m), 1491 (m), 1470 (w), 1431 (m), 1393 (w), 1360 (m), 1325 (w), 1306 (w), 1288 (w), 1252 (w), 1206 (w), 1153 (w), 1115 (m), 1105 (w), 1049 (m), 1007 (w), 945 (m), 914 (w), 870 (w), 760 (s), 727 (s), 700 (m), 687 (s), 667 (m), 650 (w), 627 (w). Anal. Calcd for C₂₆H₁₇N₃ (371.4): C, 84.07; H, 4.61; N, 11.31. Found: C, 83.90; H, 4.76; N, 11.39.

2-[(4-Methoxyphenyl)ethynyl]-3-(1-phenyl-1H-pyrrol-2-yl)quinoxaline (5m). Greenish solid (589 mg, 73%). $R_f = 0.39$ (dichloromethane). Mp: 137 °C. ¹H NMR (CDCl₃, 300 MHz): δ 3.85 (s, 3 H), 6.50 (dd, J = 3.7 Hz, J = 2.8 Hz, 1 H), 6.88-6.96 (m, 2 H), 7.12-7.19 (m, 3 H), 7.19-7.25 (m, 3 H), 7.28 (dd, J = 3.8 Hz, J = 1.7 Hz, 1 H), 7.51-7.57 (m, 2 H), 7.57-7.68 (m, 3 H), 7.98-8.04 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 55.3 (CH₃), 87.3 (C_{quat}), 95.6 (C_{quat}), 109.5 (CH), 113.9 (C_{quat}), 114.2 (CH), 116.1 (CH), 125.2 (CH), 126.4 (CH), 126.5 (CH), 128.4 (CH), 128.76 (CH), 128.79 (CH), 129.2 (C_{guat}), 129.7 (CH), 130.1 (CH), 134.0 (CH), 138.7 (C_{quat}), 139.90 (C_{quat}), 139.93 (C_{quat}), 140.9 (C_{quat}), 147.9 (C_{quat}), 160.6 (C_{quat}). MALDI-MS: $m/z = 402 \text{ [MH^+]}$. IR (solid): $\tilde{\nu}$ 3672 (w), 3055 (w), 2988 (m), 2972 (m), 2937 (m), 2901 (m), 2540 (w), 2351 (w), 2208 (w), 1599 (m), 1543 (m), 1497 (m), 1468 (m), 1429 (m), 1416 (m), 1393 (m), 1360 (m), 1287 (m), 1248 (m), 1206 (m), 1153 (m), 1115 (m), 1101 (m), 1057 (s), 1042 (s), 1028 (s), 1003 (m), 947 (m), 937 (w), 870 (w), 827 (s), 760 (s), 743 (m), 727 (s), 698 (s), 662 (m), 625 (m). Anal. Calcd for C₂₇H₁₉N₃O (401.5): C, 80.78; H, 4.77; N, 10.47. Found: C, 80.57; H, 4.60; N, 10.50.

2-[(4-Cyanophenyl)ethynyl]-3-(1-phenyl-1H-pyrrol-2-yl)quinoxaline (5n). The compound was obtained as a yellow solid (536 mg, 68%). R_f = 0.12 (dichloromethane). Mp: 214 °C. ¹H NMR $(CDCl_3, 300 \text{ MHz}): \delta 6.50 \text{ (dd, } J = 3.8 \text{ Hz}, J = 2.8 \text{ Hz}, 1 \text{ H}), 7.11 - 100 \text{ Hz}$ 7.18 (m, 3 H), 7.20-7.28 (m, 4 H), 7.63-7.72 (m, 7 H), 7.99-8.04 (m, 1 H). ^{13}C NMR (CDCl₃, 75 MHz): δ 91.6 (C_{quat}), 92.0 (C_{quat}), 109.7 (CH), 112.7 (C_{quat}), 116.1 (CH), 118.2 (C_{quat}), 125.1 (CH), 126.56 (CH), 126.63 (C_{quat}), 126.8 (CH), 128.6 (CH), 128.8 (C_{quat}), 128.85 (CH), 128.88 (CH), 130.0 (CH), 131.0 (CH), 132.1 (CH), 132.6 (CH), 137.3 (C_{quat}), 139.9 (C_{quat}), 140.3 (C_{quat}), 140.8 (C_{quat}), 147.9 (C_{quat}). MALDI-MS: m/z = 397.3 [MH⁺]. IR (solid): $\tilde{\nu} \ 3057$ (w), 2222 (w), 1595 (w), 1543 (w), 1520 (w), 1495 (m), 1472 (w), 1429 (m), 1395 (w), 1358 (m), 1323 (w), 1277 (w), 1252 (w), 1221 (w), 1198 (w), 1171 (w), 1153 (w), 1115 (m), 1096 (m), 1074 (w), 1047 (m), 1036 (w), 1013 (w), 945 (m), 908 (w), 870 (w), 827 (m), 795 (w), 760 (s), 725 (s), 689 (m), 664 (m). Anal. Calcd for C₂₇H₁₆N₄ (396.4): C, 81.80; H, 4.07; N, 14.13. Found: C, 81.57; H, 4.08: N. 14.05.

2-[1-(*Triisopropylsilyl*)-1*H*-pyrrol-3-yl]-3-[(*trimethylsily*)]ethynyl]quinoxaline (**50**). Yellow solid (496 mg, 55%. $R_f = 0.26$ (petroleum ether/ethyl acetate 20:1. Mp: 119 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.34 (s, 9 H), 1.16 (d, J = 7.5 Hz, 18 H), 1.54 (sept, J = 7.5 Hz, 3 H), 6.86 (dd, J = 2.8 Hz, J = 2.1 Hz, 1 H), 7.37 (dd, J = 2.9 Hz, J = 1.4 Hz, 1 H), 7.60 (ddd, J = 8.3 Hz, J = 6.9 Hz, J = 1.5 Hz, 1 H), 7.67 (ddd, J =8.3 Hz, J = 6.9 Hz, J = 1.7 Hz, 1 H), 7.96–8.04 (m, 3 H). ¹³C NMR (CDCl₃, 75 MHz): δ –0.4 (CH₃), 11.7 (CH), 17.8 (CH₃), 100.5 (Cquat), 104.3 (Cquat), 112.0 (CH), 124.3 (Cquat), 124.9 (CH), 127.5 (CH), 128.5 (CH), 128.59 (CH), 128.62 (CH), 130.4 (CH), 136.0 (Cquat), 139.8 (Cquat), 141.2 (Cquat), 149.7 (Cquat). MALDI-MS: m/z =448 [MH⁺]. IR (solid): $\tilde{\nu}$ 2945 (w), 2924 (w), 2866 (w), 2361 (w), 1539 (m), 1522 (w), 1493 (m), 1456 (w), 1319 (w), 1248 (m), 1227 (w), 1202 (m), 1128 (m), 1105 (s), 1086 (w), 1072 (w), 1034 (w), 1016 (w), 995 (w), 959 (w), 934 (w), 883 (m), 843 (s), 816 (m), 797 (m), 768 (s), 727 (m), 691 (s), 662 (s), 650 (m), 633 (m), 631 (m). Anal. Calcd for $C_{26}H_{37}N_3Si_2$ (447.8): C, 69.74; H, 8.33; N, 9.38. Found: C, 69.50; H, 8.24; N, 9.11.

2-(5-Methoxythiophene-2-yl)-3-[(trimethylsilyl)ethynyl]quinoxaline (5p). Yellow solid (398 mg, 59%). $R_f = 0.24$ (petroleum ether/ethyl acetate 20:1). Mp: 148 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.37 (s, 9 H), 3.99 (s, 3 H), 6.28 (d, J = 4.3 Hz, 1 H), 7.62 (ddd, J = 8.2 Hz, J = 6.9 Hz, J = 1.6 Hz, 1 H), 7.68 (ddd, J = 8.3 Hz, J = 6.9 Hz, J = 1.7 Hz, 1 H), 7.94 (ddd, J = 8.3 Hz, J = 1.7 Hz, J = 0.7 Hz, 1 H), 7.99 (ddd, J = 8.3 Hz, J = 1.7 Hz, J = 0.7 Hz, 1 H), 8.35 (d, J = 4.3 Hz, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ –0.6 (CH₃), 60.1 (CH₃), 102.2 (C_{quat}),103.4 (C_{quat}), 105.2 (CH), 128.1 (C_{quat}), 128.3 (CH), 128.6 (CH), 129.1 (CH), 129.9 (CH), 130.9 (CH), 134.1 (C_{quat}), 139.7 (C_{quat}) , 140.6 (C_{quat}) 147.5 (C_{quat}) , 171.3 (C_{quat}) . EI + MS (m/z): 340 (11), 339 (26), 338 (M⁺, 100), 323 ([M - CH₃]⁺, 9), 308 ([M - $(CH_3)_2$, 6), 307 ([M-OCH₃], 4), 295 (11), 293 ([M - (CH₃)₃]⁺, 4), 280 (13), 279 (10), 265 ([M-Si(CH₃)₃]⁺, 7), 205 (21), 140 (11), 43 (25). IR (solid): $\tilde{\nu}$ 2953 (w), 2897 (w), 2154 (w), 1551 (w), 1479 (s), 1452 (m), 1418 (s), 1395 (m), 1358 (w), 1339 (m), 1310 (w), 1250 (m), 1215 (s), 1180 (m), 1134 (m), 1125 (w), 1067 (s), 986 (m), 939 (w), 845 (s), 810 (w), 750 (s), 737 (m), 725 (w), 702 (w), 640 (w), 625 (w). Anal. Calcd for C₁₈H₁₈N₂OSSi (338.5): C, 63.87; H, 5.36; N, 8.28. Found: C, 63.64; H, 5.64; N, 8.00.

2-(5-Methoxythiophene-2-yl)-3-(phenylethynyl)quinoxaline (5a). Yellow crystals (192 mg, 28%). $R_f = 0.16$ (petroleum ether/ethyl acetate 10:1). Mp: 164 °C. ¹H NMR (CDCl₃, 300 MHz): δ 3.99 (s, 3 H), 6.31 (d, J = 4.3 Hz, 1 H), 7.40-7.47 (m, 3 H), 7.60-7.73 (m, 4 H), 7.91–7.98 (m, 1 H), 8.01 (dd, J = 8.1 Hz, J = 1.3 Hz, 1 H), 8.31 (d, J = 4.3 Hz, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 60.1 (CH₃), 88.6 (C_{quat}) , 94.9 (C_{quat}) , 105.5 (CH), 121.7 (C_{quat}) , 128.2 (C_{quat}) , 128.4 (CH), 128.55 (CH), 128.59 (CH), 129.1 (CH), 129.5 (CH), 129.7 (CH), 130.8 (CH), 132.1 (CH), 134.7 (C_{quat}), 139.9 (C_{quat}), 140.6 (C_{quat}), 147.5 (C_{quat}), 171.2 (C_{quat}). EI + MS (m/z): 343 (24), 342 (M⁺, 100), 328 (10), 327 ([M - CH₃]⁺, 46), 300 (17), 299 (72), 298 (30), 267 (13), 156 (17), 155 (11), 149 (16), 128 (21), 127 (21). IR (solid): $\tilde{\nu}$ 3065 (w), 2933 (w), 2210 (w), 1543 (w), 1477 (s), 1452 (w), 1416 (s), 1396 (m), 1285 (w), 1258 (w), 1209 (m), 1150 (w), 1132 (m), 1111 (m), 1059 (m), 1024 (w), 995 (m), 953 (w), 934 (m), 908 (w), 874 (w), 847 (w), 824 (w), 777 (m), 760 (m), 754 (s), 737 (m), 723 (m), 690 (s), 664 (m), 622 (m), 611 (m). Anal. Calcd for C₂₁H₁₄N₂OS (342.4): C, 73.66; H, 4.12; N, 8.18, S 9.36. Found: C, 73.89; H, 4.18; N, 8.10, S 9.32.

2-[(4-Methoxyphenyl)ethynyl]-3-(5-methoxythiophene-2-yl)quinoxaline (5r). Yellow crystals (243 mg, 33%). $R_f = 0.15$ (petroleum ether/ethyl acetate 5:1). Mp: 120 °C. ¹H NMR (CDCl₃, 300 MHz): δ 3.85 (s, 3 H), 3.99 (s, 3 H), 6.31 (d, J = 4.3 Hz, 1 H), 6.94 (d, J = 8.6 Hz, 2 H), 7.56–7.75 (m, 4 H), 7.87–8.08 (m, 2 H), 8.32 (dd, J = 4.3 Hz, 1 H). $^{13}\mathrm{C}$ NMR (CDCl_3, 75 MHz): δ 55.4 (CH_3), 60.1 (CH_3), 87.8 (Cquat), 95.5 (Cquat), 105.4 (CH), 113.7 (Cquat), 114.3 (CH), 128.26 (C_{quat}), 128.33 (CH), 128.5 (CH), 129.1 (CH), 129.5 (CH), 130.5 (CH), 133.7 (CH), 135.0 (C_{quat}), 140.0 (C_{quat}), 140.4 (C_{quat}), 147.5 (C_{quat}), 160.76 (C_{quat}), 171.1 (C_{quat}). EI + MS (m/z): 373 (24), $372 (M^+, 100), 357 ([M^- CH_3]^+, 12), 342 ([M - (CH_3)_2]^+, 9), 330$ (17), 329 (76), 314 (39), 298 (15), 286 (34), 285 (17), 165 (25), 157 $(C_{10}H_7NO^+, 10)$, 149 (10), 143.4 (15), 142.6 (29). IR (solid): $\tilde{\nu}$ 3059 (w), 3046 (w), 2933 (w), 2830 (w), 2207 (m), 1603 (m), 1551 (w), 1510 (m), 1489 (s), 1474 (m), 1454 (m), 1423 (m), 1398 (m), 1352 (m), 1292 (m), 1246 (s), 1204 (s), 1182 (m), 1132 (m), 1113 (m), 1061 (s), 1034 (s), 995 (m), 935 (m), 910 (w), 841 (m), 808 (m), 779 (s), 758 (s), 723 (m), 646 (w), 608 (m). Anal. Calcd for C₂₂H₁₆N₂O₂S (372.4): C, 70.95; H, 4.33; N, 7.52. Found: C, 70.69; H, 4.47; N, 7.31.

2-(Azulen-1-yl)-3-[(trimethylsilyl)ethynyl]quinoxaline (**5s**). Dark green solid (437 mg, 62%). $R_f = 0.28$ (petroleum ether/ethyl acetate 10:1). Mp: 105 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.19 (s, 9 H), 7.30–7.43 (m, 2 H), 7.46 (d, J = 4.1 Hz, 1 H), 7.64–7.83 (m, 3 H), 8.10–8.15 (m, 2 H), 8.46 (d, J = 9.5 Hz, 1 H), 8.75 (d, J = 4.1 Hz, 1 H), 9.15 (d, J = 9.7 Hz, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ –0.7 (CH₃), 101.6 (C_{quat}), 103.5 (C_{quat}), 117.1 (CH), 124.3 (C_{quat}), 125.1 (CH), 125.9 (CH), 128.78 (CH), 128.83 (CH), 129.4 (CH),

130.7 (CH), 137.1 (CH), 137.5 (CH), 138.5 (C_{quat}), 138.6 (CH), 139.1 (C_{quat}), 139.4 (CH), 139.8 (C_{quat}), 140.8 (C_{quat}), 143.4 (C_{quat}), 152.3 (C_{quat}). EI + MS (*m*/*z*): 353 (29), 352 (M⁺, 100), 351 (82), 337 ([M - CH₃]⁺, 15), 307 ([M - (CH₃)₂]⁺, 9), 293 (16), 280 (10), 279 ([M-Si(CH₃)₃]⁺, 26), 228 (26), 227 (10), 153 (C₁₁H₇N, 18). IR (solid): $\tilde{\nu}$ 3053 (w), 2958 (w), 1524 (w), 1504 (w), 1472 (w), 1422 (w), 1396 (m), 1310 (w), 1296 (w), 1250 (w), 1207 (m), 1190 (w), 1136 (w), 1123 (w), 1088 (w), 1051 (w), 1003 (w), 957 (w), 924 (w), 912 (w), 872 (w), 843 (s), 800 (w), 781 (s), 758 (s), 733 (m), 706 (w), 631 (w), 613 (m). Anal. Calcd for C₂₃H₂₀N₂Si (352.5): C, 78.37; H, 5.72; N, 7.95. Found: C, 78.28; H, 5.48; N, 7.94.

6,7-Dichloro-2-(1-methyl-1H-indol-3-yl)-3-[(trimethylsilyl)ethynyl]quinoxaline (5t). Yellow solid (686 mg, 81%). $R_f = 0.90$ (dichloromethane). Mp: 237 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.39 (s, 9 H), 3.89 (s, 3 H), 7.30–7.41 (m, 3 H), 8.07 (d, J = 0.4 Hz, 1 H), 8.15 (d, J = 0.4 Hz, 1 H), 8.63 (s, 1 H), 8.71-8.77 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ -0.5 (CH₃), 33.4 (CH₃), 102.3 (C_{mut}), 104.0 (C_{quat}), 109.5 (CH), 111.6 (C_{quat}), 121.8 (CH), 123.2 (CH), 123.2 (CH), 127.3 (C_{quat}), 129.0 (CH), 130.9 (CH), 132.6 (C_{quat}), 133.4 (CH), 134.8 (C_{quat}), 136.9 (C_{quat}), 137.2 (C_{quat}), 137.5 (C_{quat}), 139.8 (C_{quat}) , 151.1 (C_{quat}) . MALDI-MS: m/z = 424.0 [MH⁺]. IR (solid): $\tilde{\nu}$ 3138 (w), 2957 (w), 2928 (w), 2895 (w), 1946 (w), 1867 (w), 1587 (w), 1516 (m), 1462 (w), 1443 (m), 1406 (w), 1400 (w), 1362 (m), 1337 (w), 1312 (w), 1285 (w), 1246 (m), 1238 (m), 1225 (w), 1198 (m), 1179 (m), 1157 (m), 1126 (w), 1099 (m), 1084 (m), 1051 (w), 1018 (w), 974 (w), 935 (m), 880 (m), 860 (m), 835 (s), 797 (w), 745 (s), 727 (m), 702 (m), 664 (m), 644 (m), 623 (m). Anal. Calcd for C₂₂H₁₉Cl₂N₃Si (424.4): C, 62.26; H, 4.51; N, 9.90. Found: C, 62.12; H, 4.35; N, 9.79.

2-(1-Methyl-1H-indol-3-yl)-6-nitro-3-[(trimethylsilyl)ethynyl]quinoxalines and 2-(1-Methyl-1H-indol-3-yl)-7-nitro-3-[(trimethylsilyl)ethynyl]quinoxaline (5u). Red solid (694 mg, 87%). $R_f = 0.58$ (dichloromethane). Mp: 232 °C. ¹H NMR (CDCl₃, 300 MHz): isomer ratio =10:1; δ 0.41 (s, 9 H), 3.92 (s, 3 H), 7.34–7.45 (m, 3 H), 8.08 (dd, J = 9.1 Hz, J = 0.5 Hz, 1 H), 8.34 (dd, J = 9.1 Hz, J = 2.5 Hz, 1 H), 8.71 (s, 1 H), 8.78–8.86 (m, 1 H), 8.91 (dd, J = 2.5 Hz, J = 0.5 Hz, 1 H); additional signals for the minor isomer: δ 8.12 (dd, J = 9.2 Hz, J = 0.5 Hz, 1 H), 8.43 (dd, J = 9.2 Hz, J = 2.5 Hz, 1H). ¹³C NMR (CDCl₃, 75 MHz): δ –0.6 (CH₃), 33.5 (CH₃), 103.91 (C_{quat}), 103.94 (C_{quat}), 109.6 (CH), 111.4 (C_{quat}), 121.7 (CH), 122.1 (CH), 123.3 (CH), 123.5 (CH), 124.6 (CH), 127.3 (C_{quat}), 130.0 (CH), 133.8 (CH), 137.3 (C_{quat}), 138.8 (C_{quat}), 140.0 (C_{quat}), 141.2 (C_{quat}) , 148.2 (C_{quat}) , 151.9 (C_{quat}) . MALDI-MS: m/z = 401.1 [MH⁺]. IR (solid): $\tilde{\nu}$ 3686 (w), 2970 (w), 2959 (w), 2901 (w), 2357 (w), 2330 (w), 1614 (w), 1516 (s), 1476 (m), 1458 (w), 1418 (w), 1408 (w), 1371 (m), 1337 (s), 1317 (w), 1287 (m), 1242 (m), 1215 (m), 1194 (m), 1159 (w), 1121 (w), 1090 (m), 1070 (m), 1057 (m), 1018 (w), 959 (w), 901 (m), 868 (m), 839 (s), 818 (m), 793 (m), 748 (s), 729 (s), 702 (m), 658 (m), 638 (m), 619 (m). Anal. Calcd for C₂₂H₂₀N₄O₂Si (400.5): C, 65.98; H, 5.03; N, 13.99. Found: C, 65.76; H, 5.15; N, 14.08.

3-(1-Methyl-1H-indol-3-yl)-2-[(triisopropylsilyl)ethynyl]pyrido-[2,3-b]pyrazine and 2-(1-Methyl-1H-indol-3-yl)-3-[(triisopropylsilyl)ethynyl]pyrido[2,3-b]pyrazine (5v). Orange resin (358 mg, 72%). R_f = 0.32 (petroleum ether/ethyl acetate 3:1). Mp: 99 °C. ¹H NMR $(CDCl_3, 300 \text{ MHz})$: isomer ratio =6.5:1; δ 1.17–1.27 (m, 21 H), 3.88 (s, 3 H), 7.27–7.47 (m, 4 H), 7.61 (dd, J = 8.3 Hz, J = 4.2 Hz, 1 H), 8.42 (dd, J = 8.3 Hz, J = 1.9 Hz, 1 H), 8.77 (s, 1 H), 8.77-8.82 (m, 1 H), 9.02 (dd, J = 4.2 Hz, J = 1.9 Hz, 1 H); additional signals for the minor isomer: δ 3.84 (s, 3 H). ¹³C NMR (CDCl₃, 75 MHz): δ 11.3 (CH), 18.7 (CH₃), 33.3 (CH₃), 100.1 (C_{quat}), 106.0 (C_{quat}), 109.5 (CH), 111.7 (C_{quat}), 121.7 (CH), 123.0 (CH), 123.1 (CH), 125.3 (CH), 127.4 (C_{quat}), 133.5 (CH), 136.5 (C_{quat}), 137.1 (CH), 137.3 (C_{quat}) , 139.2 (C_{quat}) , 148.1 (C_{quat}) , 151.3 (C_{quat}) , 151.4 (CH). Additional signals for the minor isomer: δ 33.6 (CH₃), 109.8 (CH), 122.6 (CH), 123.7 (CH), 140.2 (CH). EI + MS (m/z): 441 (36), 440 $(M^+, 100), 398 (13), 397 ([M - C_3H_7]^+, 41), 356 (13), 355 (41), 354$ $([M - (C_3H_7)_2]^+, 8), 327 (28), 318 (19), 325 (12), 311 ([M -$ $(C_{3}H_{7})_{3}^{+}, 47), 163 (12), 158 (21), 156 (15), 155 (12), 135 (13).$ IR (solid): $\tilde{\nu}$ 2941 (w), 2887 (w), 2862 (w), 1609 (w), 1591 (w),

1533 (s), 1522 (s), 1480 (w), 1464 (m), 1452 (m), 1435 (m), 1373 (s), 1339 (w), 1304 (w), 1279 (m), 1240 (s), 1207 (m), 1186 (w), 1159 (m), 1142 (w), 1117 (m), 1086 (m), 1015 (w), 997 (w), 935 (m), 883 (m), 839 (m), 824 (w), 791 (w), 761 (s), 741 (s), 681 (s), 654 (s), 611 (s). Anal. Calcd for $C_{27}H_{32}N_4Si$ (440.6): C, 73.59; H, 7.32; N, 12.71. Found: C, 73.74; H, 7.28; N, 12.54.

2-(1-Methyl-1H-indol-3-yl)-3-[(trimethylsilyl)ethynyl]benzo[g]quinoxaline (5w). Orange solid (537 mg, 66%). $R_f = 0.65$ (dichloromethane). Mp: 251 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.39 (s, 9 H), 3.92 (s, 3 H), 7.35–7.45 (m, 3 H), 7.48–7.58 (m, 2 H), 8.02–8.12 (m, 2 H), 8.59 (s, 1 H), 8.64 (s, 2 H), 8.87–8.95 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ –0.5 (CH₃), 33.4 (CH₃), 101.4 (C_{quat}), 104.7 (C_{quat}), 109.4 (CH), 112.3 (C_{quat}), 121.6 (CH), 123.1 (CH), 123.3 (CH), 126.16 (CH), 126.19 (CH), 127.0 (CH), 127.1 (CH), 127.6 (C_{quat}), 136.2 (C_{quat}), 137.3 (C_{quat}), 137.6 (C_{quat}), 137.7 (C_{quat}), 149.8 (C_{quat}). MALDI-MS: m/z = 406 [MH⁺]. IR (solid): $\tilde{\nu}$ 3046 (w), 2951 (w), 2891 (w), 1528 (s), 1474 (w), 1464 (w), 1447 (w), 1420 (w), 1369 (m), 1339 (w), 1296 (w), 1260 (w), 1248 (m), 1229 (m), 1215 (w), 1177 (w), 1159 (w), 1130 (w), 1088 (m), 1053 (w), 1016 (w), 937 (w), 870 (m), 843 (s), 793 (w), 770 (w), 748 (s), 737 (s), 702 (w), 691 (w), 642 (w), 627 (m), 605 (w). Anal. Calcd for C₂₆H₂₃N₃Si (405.6): C, 77.00; H, 5.72; N, 10.36. Found: C, 76.78; H, 5.87; N, 10.32.

2-(1-Methyl-1H-indol-3-yl)-3-(phenylethynyl)benzo[q]quinoxaline (5x). Orange solid (349 mg, 43%). $R_f = 0.87$ (dichloromethane). Mp: 249 °C. ¹H NMR (CDCl₃, 300 MHz): δ 3.92 (s, 3 H), 7.36-7.49 (m, 6 H), 7.50-7.59 (m, 2 H), 7.63-7.66 (m, 2 H), 8.08 (d, J = 9.6 Hz, 2 H) 8.53 (s, 1 H), 8.61 (s, 1 H), 8.67 (s, 1 H), 8.85–8.91 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ 33.5 (CH₃), 90.1 (C_{quat}), 94.5 (C_{quat}), 109.5 (CH), 112.6 (C_{quat}), 121.6 (CH), 121.9 (C_{quat}), 123.1 (CH), 123.2 (CH), 126.2 (CH), 126.3 (CH), 126.9 (CH), 127.0 (CH), 127.6 (C_{quat}), 128.3 (CH), 128.68 (CH), 128.73 (CH), 129.7 (CH), 132.0 (CH), 133.0 (CH), 133.3 (C_{quat}), 134.6 (C_{quat}), 136.5 (C_{quat}), 137.4 (C_{quat}) 137.6 (C_{quat}), 138.3 (C_{quat}), 150.1 (C_{quat}). EI + MS (m/z): 410 (23), 409 (M⁺, 88), 408 (100), 394 ([M - CH₃]⁺, 11), 332 ([M - Ph]⁺, 3), 282 ($C_{20}H_{14}N_2^+$, 5), 281 (12), 204.4 (20), 203.5 (18), 197 (13), 156 (17), 155 (12), 126 (24). IR (solid): $\tilde{\nu}$ 2207 (w), 1520 (m), 1489 (w), 1441 (w), 1423 (w), 1371 (m), 1341 (w), 1306 (w), 1285 (w), 1148 (w), 1117 (m), 1084 (m), 1013 (w), 997 (w), 937 (w), 908 (w), 874 (m), 837 (w), 773 (m), 741 (s), 683 (s), 658 (w), 624 (m), 611 (w). Anal. Calcd for C₂₉H₁₉N₃ (409.5): C, 85.06; H, 4.68; N, 10.26. Found: C, 84.93; H, 4.49; N, 10.38.

General Procedure for the Three-Component Synthesis of 3-Ethynylquinoxalines 7. A 2.00 mmol portion of glyoxylic acid 7 in dry 1,4-dioxane (2.5 mL/mmol) was placed under argon or nitrogen atmosphere in a screw-cap Schlenk tube and degassed with argon or nitrogen (for experimental details, see Table 8). Then, oxalyl chloride

Table 8. Experimental Details for the Three-ComponentSynthesis of 2-Substituted 3-Ethynylquinoxalines 7

entry	glyoxylic acid 6	3-ethynylquinoxaline 7 (yield, %) b
1	300 mg (2.00 mmol) of 6a	515 mg (85%) of 7a
2	384 mg (2.00 mmol) of 6b	178 mg (26%) of 7b
3	280 mg (2.00 mmol) of 6c	178 mg (30%) of 7c
4	312 mg (2.00 mmol) of 6d	427 mg (69%) of 7d
^a All	compounds were prepared on	a 2.00 mmol scale. ^b Yields after

chromatography on silica gel.

(0.18 mL, 2.00 mmol, 1.0 equiv) was added dropwise to the reaction mixture. The mixture was stirred at room temperature (water bath) for 5 min and then at 50 °C for 4 h. Thereafter, the mixture was cooled to room temperature (water bath, 5 min). Then, CuI (20 mg, 0.1 mmol, 5 mol %), trimethylsilylacetylene (2b) (0.28 mL, 2.00 mmol, 1 equiv), and dry triethylamine (0.84 mL, 6.00 mmol, 3.0 equiv) were successively added to the reaction mixture, and stirring at room temperature was continued for 15 h. Then, 2 mL of methanol, 216 mg of 1,2-diaminobenzene (4a) (2.00 mmol, 1.0 equiv), and 2 mL of acetic acid were added successively, and the mixture was stirred at

ethyl acetate or dichloromethane to give the 3-ethynylquinoxalines 7. 2-Phenyl-3-[(trimethylsilyl)ethynyl]quinoxaline (7a). Colorless oil (515 mg, 85%). $R_f = 0.28$ (petroleum ether/ethyl acetate 20:1). ¹H NMR (CDCl₃, 300 MHz): δ 0.22 (s, 9 H), 7.47–7.54 (m, 3 H), 7.72–7.79 (m, 2 H), 8.03–8.15 (m, 4 H). ¹³C NMR (CDCl₃, 75 MHz): δ –0.71 (CH₃), 102.1 (C_{quat}), 102.7 (C_{quat}), 127.9 (CH), 128.8 (CH), 129.2 (CH), 129.6 (CH), 129.7 (CH), 130.2 (CH), 130.8 (CH), 137.3 (C_{quat}), 137.5 (C_{quat}), 140.76 (C_{quat}), 154.9 (C_{quat}). EI + MS (m/z): 303 (12), 302 (M⁺, 47), 301 (61), 288 (25), 287 ([M – CH₃]⁺, 100), 272 ([M – (CH₃)₂]⁺, 6), 271 (11), 257 (22). IR (solid): $\tilde{\nu}$ 3061 (w), 2959 (w), 2897 (w), 2160 (w), 1609 (w), 1557 (m), 1530 (w), 1477 (w), 1393 (w), 1335 (m), 1308 (m), 1285 (w), 1250 (m), 1217 (w), 1188 (w), 1130 (m), 1123 (w), 1076 (w), 1036 (w), 997 (w), 912 (w), 839 (2), 820 (m), 758 (s), 729 (m), 692 (s), 635 (m), 606 (m). HR-MS: mass calcd for C₁₉H₁₈N₂Si⁻H⁺ 303.13175, found 303.13120.

gel with solvent mixtures of petroleum ether (boiling range 40-60 °C) and

2-Mesityl-3-[(trimethylsilyl)ethynyl]quinoxaline (7b). Colorless solid (178 mg, 26%). $R_f = 0.32$ (petroleum ether/ethyl acetate 20:1). Mp: 101 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.03 (s, 9 H), 2.01 (s, 6 H), 2.34 (s, 3H), 6.95 (s, 2 H), 7.74-7.81 (m, 2 H), 8.08-8.16 (m, 2 H). ¹³C NMR (CDCl₃, 75 MHz): δ -0.9 (CH₃), 19.7 (CH₃), 21.1 (CH₃), 101.3 (C_{quat}), 102.0 (C_{quat}), 128.1 (CH), 129.0 (CH), 129.3 (CH), 130.2 (CH), 130.5 (CH), 134.3 (C_{quat}), 135.8 (C_{quat}) , 138.3 (C_{quat}) 139.8 (C_{quat}) 140.78 (C_{quat}) , 140.83 (C_{quat}) , 158.1 (C_{quat}) . EI + MS (m/z): 345 (30), 344 $(M^+, 100)$, 343 (38), 330 (13), 329 ([M - CH₃]⁺, 47), 157 (14), 147 (58), 119 (C₉H₁₁⁺, 13). IR (solid): v 2959 (w), 2918 (w), 2853 (w), 2162 (w), 1652 (w), 1613 (m), 1589 (w), 1556 (w), 1539 (m), 1456 (w), 1433 (w), 1379 (w), 1329 (m), 1314 (w), 1192 (m), 1157 (w), 1130 (m), 1119 (m), 1065 (w), 1036 (w), 1013 (w), 1001 (w), 986 (w), 949 (w), 912 (w), 839 (s), 812 (m), 766 (s), 739 (m), 700 (w), 669 (m), 650 (m), 631 (m), 608 (m). Anal. Calcd for C22H24N2Si (344.5): C, 76.70; H, 7.02; N, 8.13. Found: C, 76.69; H, 6.80; N, 7.83.

2-(Furan-2-yl)-3-[(trimethylsilyl)ethynyl]quinoxaline (7c). Beige solid (178 mg, 30%). $R_f = 0.26$ (petroleum ether/ethyl acetate 10:1). Mp: 78 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.37 (s, 9 H), 6.62 (dd, J = 3.6 Hz, J = 1.8 Hz, 1 H), 7.66–7.79 (m, 3 H), 7.88 (dd, J = 3.6 Hz, J = 0.7 Hz, 1 H), 8.02–8.08 (m, 1 H), 8.10–8.16 (m, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ –0.6 (CH₃), 102.6 (C_{quat}), 102.7 (C_{quat}) 111.9 (CH), 115.6 (CH), 128.9 (CH), 129.1 (CH), 130.1 (CH), 131.2 (CH), 134.8 (C_{quat}), 140.2 (C_{quat}), 140.5 (C_{quat}), 143.9 (C_{quat}), 145.4 (CH), 149.8 (C_{quat}). EI + MS (m/z): 293 (19), 292 (M⁺, 80), 278 (24), 277 ($[M - (\dot{C}H_3)]^+$, 100), 262 ($(M - (CH_3)_2)^+$, 4), 247 ((M $-(CH_3)_3^+, 19)$. IR (solid): $\tilde{\nu}$ 3142 (w), 3123 (w), 2955 (w), 2924 (w), 2899 (w), 2853 (w), 2164 (w), 1611 (w), 1574 (w), 1522 (w), 1472 (w), 1451 (w), 1404 (w), 1335 (m), 1314 (w), 1252 (w), 1225 (w), 1196 (m), 1163 (w), 1132 (m), 1123 (w), 1083 (w), 1040 (w), 1007 (w), 962 (w), 923 (w), 885 (w), 841 (s), 800 (w), 760 (s), 739 (m), 700 (w), 664 (w), 633 (m) 621 (m). Anal. Calcd for C₁₇H₁₆N₂OSi (292.4): C, 69.83; H, 5.52; N, 9.58. Found: C, 69.58; H, 5.48; N, 9.36.

2-(Thiophene-2-yl)-3-[(trimethylsilyl)ethynyl]quinoxaline (7d). Light yellow solid (427 mg, 69%). $R_f = 0.30$ (petroleum ether/ethyl acetate 25:1). Mp: 81 °C. ¹H NMR (CDCl₃, 300 MHz): δ 0.37 (s, 9 H), 7.18 (dd, J = 5.1 Hz, J = 3.9 Hz, 1 H), 7.56 (dd, J = 5.1 Hz, J = 1.0 Hz, 1 H), 7.65–7.76 (m, 2 H), 8.00–8.07 (m, 2 H), 8.55 (dd, J = 3.8 Hz, J = 1.0 Hz, 1 H). ¹³C NMR (CDCl₃, 75 MHz): δ –0.6 (CH₃), 102.6 (C_{quat}), 103.1 (C_{quat}), 127.8 (CH), 128.7 (CH), 128.8 (CH), 129.9 (CH), 130.2 (CH), 130.4 (CH), 131.0 (CH), 134.8 (C_{quat}), 140.3 (C_{quat}), 140.6 (C_{quat}) 141.8 (C_{quat}) 147.6 (C_{quat}). EI + MS (m/z): 309 (15), 308 (M⁺, 54), 307 (26), 293 ([M – (CH₃)]⁺, 100), 263 (20). IR (solid): $\tilde{\nu}$ 2957 (w), 1526 (w), 1474 (w), 1427 (w), 1335 (m), 1248 (m), 1230 (w), 1217 (w), 1180 (w), 1134 (w), 1082 (w), 1058 (w), 947 (w), 912 (w), 843 (s), 810 (m), 759 (s), 739 (m), 716 (s), 708 (s), 662 (w), 631 (m), 617 (m). Anal. Calcd for C₁₇H₁₆N₂SSi (308.5): C, 66.19; H, 5.23; N, 9.08. Found: C, 65.97; H, 5.43; N, 8.90.

ASSOCIATED CONTENT

S Supporting Information

Experimental data on the optimization study for the synthesis of ynediones 3. Selected ¹H and ¹³C NMR spectra of compounds 5a–x and 7a–d, selected absorption and emission spectra of compounds 5a, 5d, 5h, 5m, and 5r. Crystallographic data of the X-ray structure analyses of compounds 5d, 5n, 5q, and 5x. Computational data and TD-DFT computed UV/vis spectra of the quinoxalines 5a, 5d, 5h, 5m, and 5r. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: thomasjj.mueller@uni-duesseldorf.de.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support of the Fonds der Chemischen Industrie, Frankfurt (Main), is gratefully acknowledged.

REFERENCES

(1) (a) Kelley, T. W.; Baude, P. F.; Gerlach, C.; Ender, D. E.; Muyres, D.; Haase, M. A.; Vogel, D. E.; Theiss, S. D. *Chem. Mater.* 2004, *16*, 4413–4422. (b) Forrest, S. R.; Thompson, M. E. *Chem. Rev.* 2007, *107*, 923–925.

(2) For diversity-oriented syntheses of functional π -systems, see: (a) Müller, T. J. J. In Functional Organic Materials. Syntheses, Strategies, and Applications; Müller, T. J. J., Bunz, U. H. F., Eds.; Wiley: Weinheim, 2007; pp 179–223. For the concept of diversity oriented synthesis, see, e.g.: (b) Burke, M. D.; Schreiber, S. L. Angew. Chem. **2004**, 116, 48–60; Angew. Chem., Int. Ed. **2004**, 43, 46–58.

(3) (a) Sunderhaus, J. D.; Martin, S. F. Chem.—Eur. J. 2009, 15, 1300–1308. (b) Isambert, N.; Lavilla, R. Chem.—Eur. J. 2008, 14, 8444–8454. (c) Orru, R. V. A.; de Greef, M. Synthesis 2003, 1471–1499. (d) Bonne, D.; Coquerel, Y.; Constantieux, T.; Rodriguez, J. Tetrahedron: Asymmetry 2010, 21, 1085–1109.

(4) (a) Tietze, L. F. Chem. Rev. **1996**, 96, 115–136. (b) Coquerel, Y.; Boddaert, T.; Presset, M.; Mailhol, D.; Rodriguez, J. In *Ideas in* Chemistry and Molecular Sciences, Vol. 1, Advances in Synthetic Chemistry; Pignataro, B., Ed.; Wiley-VCH: Weinheim, 2010; Chapter 9, pp 187–202.

(5) (a) D'Souza, D. M.; Müller, T. J. J. Chem. Soc. Rev. 2007, 36, 1095–1108. (b) Müller, T. J. J. Top. Heterocycl. Chem. 2010, 25, 25–94.

(6) (a) Tietze, L. F.; Modi, A. Med. Res. Rev. 2000, 20, 304–322.
(b) Touré, B. B.; Hall, D. G. Chem. Rev. 2009, 109, 4439–4486.
(c) Cordier, C.; Morton, D.; Murrison, S.; Nelson, A.; O'Leary-Steele, C. Nat. Prod. Rep. 2008, 25, 719–737.

(7) (a) Ishikura, M.; Abe, T.; Choshi, T.; Hibino, S. Nat. Prod. Rep. **2013**, 30, 694–752. (b) O'Hagan, D. Nat. Prod. Rep. **2000**, 17, 435–446.

(8) (a) Bay, S.; Villnow, T.; Ryseck, G.; Rai-Constapel, V.; Gilch, P.; Müller, T. J. J. ChemPlusChem **2013**, 78, 137–141. (b) Cinar, R.; Nordmann, J.; Dirksen, E.; Müller, T. J. J. Org. Biomol. Chem. **2013**, 11, 2597–2604. (c) Dostert, C.; Wanstrath, C.; Frank, W.; Müller, T. J. J. Chem. Commun. **2012**, 48, 7271–7273. (d) Meyer, T.; Ogermann, D.; Pankrath, A.; Kleinermanns, K.; Müller, T. J. J. Org. Chem. **2012**, 77, 3704–3715.

(9) Seitz, L. E.; Suling, W. J.; Reynolds, R. C. J. Med. Chem. 2002, 45, 5604–5606.

(10) Kim, Y. B.; Kim, Y. H.; Park, J. Y.; Kim, S. K. Bioorg. Med. Chem. Lett. 2004, 541–544.

(11) Amin, K. M.; Ismail, M. M. F.; Noaman, E.; Soliman, D. H.; Ammar, Y. A. Bioorg. Med. Chem. 2006, 14, 6917–6923.

(12) (a) Woody, K. B.; Henry, E. M.; Jagtap, S.; Collard, D. M. *Macromolecules* 2011, 44, 9118–9124. (b) Zhao, Q.; Li, R.-F.; Xing, S.-K.; Liu, X.-M.; Hu, T.-L.; Bu, X.-H. *Inorg. Chem.* 2011, 50, 10041–10046. (c) Pan, Y.; Sheng, Z.; Ye, X.; Ao, Z.; Chu, G.; Dai, J.; Yu, S. J. *Photochem. Photobiol. A* 2005, 174, 98–105. (d) Anguloa, G.; Dobkowskia, J.; Kapturkiewicza, A.; Maciolek, K. J. *Photochem. Photobiol. A* 2010, 213, 101–106. (e) Schaffroth, M.; Lindner, B. D.; Vasilenko, V.; Rominger, F.; Bunz, U. H. F. J. Org. Chem. 2013, 78, 3142–3150. (f) Rao, M. R.; Liao, C.-W.; Su, W.-L.; Sun, S.-S. J. Mater. Chem. C 2013, 1, 5491–5501. (g) Pina, J.; Seixas de Melo, J.; Breusov, D.; Scherf, U. Phys. Chem. Chem. Phys. 2013, 15, 15204–15213.

(13) Kudo, K.; Momotake, A.; Kanna, Y.; Nishimuraa, Y.; Arai, T. *Chem. Commun.* **2011**, *47*, 3867–3869.

(14) Lin, T. C.; Chien, W.; Liu, C. Y.; Tsai, M.-Y.; Huang, Y.-J. Eur. J. Org. Chem. 2013, 4262–4269.

(15) Faust, R.; Weber, C. Tetrahedron 1997, 53, 14655-14670.

(16) Mitzel, F.; FitzGerald, S.; Beeby, A.; Faust, R. Chem.—Eur. J. 2003, 9, 1233-1241.

(17) Merkul, E.; Dohe, J.; Gers, C.; Rominger, F.; Müller, T. J. J. Angew. Chem. 2011, 123, 2023–2026; Angew. Chem., Int. Ed. 2011, 50, 2966–2969.

(18) (a) Sonogashira, K.; Tohda, Y.; Hagihara, N. *Tetrahedron Lett.* **1975**, *16*, 4467–4470. (b) Tohda, Y.; Sonogashira, K.; Hagihara, N. *Synthesis* **1977**, 777–778.

(19) Merkul, E.; Oeser, T.; Müller, T. J. J. Chem.—Eur. J. 2009, 15, 5006–5011.

(20) (a) Chowdhury, C.; Kundu, N. G. *Tetrahedron* **1999**, *55*, 7011–7016. (b) Wang, J.-X.; Wei, B.; Hu, Y.; Liu, Z.; Fu, Y. Synth. Commun. **2001**, *31*, 3527–3532.

(21) Boersch, C.; Merkul, E.; Müller, T. J. J. Angew. Chem. 2011, 123, 10632–10636; Angew. Chem., Int. Ed. 2011, 50, 10448–10452.

(22) Ynediones: (a) Mukherjee, A. K.; Margaretha, P.; Agosta, W. C. J. Org. Chem. **1996**, 61, 3388–3391. 2-Oxobutynoates: (b) François-Endelmond, C.; Carlin, T.; Thuery, P.; Loreau, O.; Taran, F. Org. Lett. **2010**, 12, 40–42. (c) Wu, Y.; Yao, W.; Pan, L.; Zhang, Y.; Ma, C. Org. Lett. **2010**, 12, 640–643. (d) Liu, Y.; Liu, M.; Guo, S.; Tu, H.; Zhou, Y.; Gao, H. Org. Lett. **2006**, 8, 3445–3448. (e) Bagley, M. C.; Dale, J. W.; Xiong, X.; Bower, J. Org. Lett. **2003**, 5, 4421–4424.

(23) Ames, D. E.; Brohi, M. I. J. Chem. Soc., Perkin Trans. 1 1980, 1384-1389.

(24) Wang, W.; Shen, Y.; Meng, X.; Zhao, M.; Chen, Y.; Chen, B. Org. Lett. **2011**, 4514–4517.

(25) Reichardt, C.; Welton, T. Solvents and Solvent Effects in Organic Chemistry, 4th ed.; Wiley-VCH: Weinheim, 2011; pp 384–393.

(26) Loving, G. S.; Sainlos, M.; Imperiali, B. *Trends Biotechnol.* **2010**, 28, 73–83.

(27) Mayr, H.; Kempf, B.; Ofial, A. R. Acc. Chem. Res. 2003, 36, 66–77.

(28) Crystallographic data (excluding structure factors) for the structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 971566 (5d), CCDC 971568 (5n), CCDC 971569 (5q), and CCDC 971567 (5x). Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (Fax: + 44-1223/336-033; E-mail: deposit@ccdc.cam.ac.uk).

(29) Boens, N.; Qin, W.; Basarić, N.; Hofkens, J.; Amelot, M.; Pouget, J.; Lefévre, J.-P.; Valeur, B.; Gratton, E.; vandeVen, M.; Silva, N. D., Jr.; Engelborghs, Y.; Willaert, K.; Sillen, A.; Rumbles, G.; Phillips, D.; Visser, A. J. W. G.; van Houk, A.; Lakowicz, J. R.; Malak, H.; Gryczynski, I.; Szabo, A. G.; Krajcarski, D. T.; Tamai, N.; Miura, A. *Anal. Chem.* **2007**, *79*, 2137–2149.

(30) Fery-Forgues, S.; Lavabre, D. J. Chem. Educ. 1999, 76, 1260–1264.

(31) See ref 25, pp 550-553.

(32) Lakowicz, J. R. Principles of Fluorescence Spectroscopy, 3rd ed.; Springer: Berlin/Heidelberg, 2006; pp 213-216.

(33) (a) Lippert, E. Z. Elektrochem. **1957**, 61, 962–975. (b) Mataga, N.; Kaifu, Y.; Koizumi, M. Bull. Chem. Soc. Jpn. **1956**, 29, 465–470.

(34) See ref 32, pp 208-213.

(35) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 09 (Revision A.02), Gaussian, Inc., Wallingford, CT, 2009.

(36) (a) Lee, C.; Yang, W.; Parr, R. G. Phys. Rev. B 1988, 37, 785– 789. (b) Becke, A. D. J. Chem. Phys. 1993, 98, 1372–1377. (c) Becke, A. D. J. Chem. Phys. 1993, 98, 5648–5652. (d) Kim, K.; Jordan, K. D. J. Phys. Chem. 1994, 98, 10089–10094. (e) Stephens, P. J.; Devlin, F. J.; Chabalowski, C. F.; Frisch, M. J. J. Phys. Chem. 1994, 98, 11623– 11627.

(37) Krishnan, R.; Binkley, J. S.; Seeger, R.; Pople, J. A. J. Chem. Phys. 1980, 72, 650-654.

(38) Scalmani, G.; Frisch, M. J. J. Chem. Phys. 2010, 132, 114110.

(39) Yanai, T.; Tew, D.; Handy, N. Chem. Phys. Lett. 2004, 393, 51-57.

(40) (a) Berezhkovski, A. M. Chem. Phys. 1992, 164, 331–339.
(b) Cammi, R.; Thomasi, J. Int. J. Quant. Chem.: Quant. Chem. Symp. 1995, 29, 465–474. (c) Mennucci, B.; Cammi, R.; Tomasi, J. J. Chem. Phys. 1998, 109, 2798–2807. (d) Li, X.-Y.; Fu, K.-X. J. Comput. Chem. 2004, 25, 500–509. (e) Cammi, R.; Corni, S.; Mennucci, B.; Tomasi, J. J. Chem. Phys. 2005, 122, 104513.